

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|--|
| (51) International Patent Classification 6 : C12N 15/82, 15/57, 15/15, 15/14, C12P 21/02 | | A1 | (11) International Publication Number: WO 98/36085 |
| | | | (43) International Publication Date: 20 August 1998 (20.08.98) |
| (21) International Application Number: PCT/US98/03068 | | (72) Inventors; and | |
| (22) International Filing Date: 13 February 1998 (13.02.98) | | (75) Inventors/Applicants (for US only): SUTLIFF, Thomas, D. [US/US]; 3405 Cook Street, Rocklin, CA 94765 (US). RODRIGUEZ, Raymond, L. [US/US]; 3017 Anza Boulevard, Davis, CA 95616 (US). | |
| (30) Priority Data: | | (74) Agents: PETITHORY, Joanne, R. et al.; Dehlinger & Associates, LLP, P.O. Box 60850, Palo Alto, CA 94306-0850 (US). | |
| 60/038,169 13 February 1997 (13.02.97) US | | | |
| 60/037,991 13 February 1997 (13.02.97) US | | | |
| 60/038,170 13 February 1997 (13.02.97) US | | | |
| 60/038,168 13 February 1997 (13.02.97) US | | | |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| US 60/038,169 (CIP) | | | |
| Filed on 13 February 1997 (13.02.97) | | | |
| US 60/037,991 (CIP) | | | |
| Filed on 13 February 1997 (13.02.97) | | | |
| US 60/038,170 (CIP) | | | |
| Filed on 13 February 1997 (13.02.97) | | | |
| US 60/038,168 (CIP) | | | |
| Filed on 13 February 1997 (13.02.97) | | | |
| (71) Applicant (for all designated States except US): APPLIED PHYTOLOGICS, INC. [US/US]; 4110 North Freeway Boulevard, Sacramento, CA 95834-1219 (US). | | Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |

(54) Title: PRODUCTION OF MATURE PROTEINS IN PLANTS



(57) Abstract

A method for producing one of the following proteins in transgenic monocot plant cells is disclosed: (i) mature, glycosylated α_1 -antitrypsin (AAT) having the same N-terminal amino acid sequence as mature AAT produced in humans and a glycosylation pattern which increases serum half-life substantially over that of mature non-glycosylated AAT; (ii) mature, glycosylated antithrombin III (ATIII) having the same N-terminal amino acid sequence as mature ATIII produced in humans; (iii) mature human serum albumin (HSA) having the same N-terminal amino acid sequence as mature HSA produced in humans and having the folding pattern of native mature HSA as evidenced by its bilirubin-binding characteristics; and (iv) mature, active subtilisin BPN' (BPN') having the same N-terminal amino acid sequence as BPN' produced in *Bacillus*. Monocot plants cells are transformed with a chimeric gene which includes a DNA coding sequence encoding a fusion protein having an (i) N-terminal moiety corresponding to a rice α -amylase signal sequence peptide and, (iii) immediately adjacent the C-terminal amino acid of said peptide, a protein moiety corresponding to the mature protein to be produced.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

Production of Mature Proteins in Plants

Field of the Invention

The present invention relates to the production of mature proteins in plant cells, and in particular, to the production of proteins in mature secreted form.

5

Background of the Invention

A major commercial focus of biotechnology is the recombinant production of proteins, including both industrial enzymes and proteins that have important therapeutic uses.

Therapeutic proteins are commonly produced recombinantly by microbial expression systems, such as in *E. coli* and the yeast system *S. cerevisiae*. To date, the cost of recombinant proteins produced in a microbial host has limited the availability of a variety of therapeutically important proteins, such as human serum albumin (HSA) and α_1 -antitrypsin (AAT), to the extent that the proteins are in short supply.

Some therapeutic proteins appear to rely on glycosylation for optimal activity or stability, and the general inability of microbial systems to glycosylate or properly glycosylate mammalian proteins has also limited the usefulness of these recombinant expression systems. In some cases, proper protein folding cannot take place, because of the need for mammalian-specific foldases or other folding conditions.

To some extent, protein expression in cultured mammalian cells, or in transgenic animals may overcome the limitations of microbial expression systems. However, the cost per weight ratio of the protein is still high in mammalian expression systems, and the risk of protein contamination by mammalian viruses may be a significant regulatory problem. Protein production by transgenic animals also carries the risk of genetic variation from one generation to another. The attendant risk is variation in the recombinant protein produced, for example, variation in protein processing to yield a nature active protein with different N-terminal residue.

It would therefore be desirable to produce selected therapeutic and industrial proteins in a protein expression system that largely overcomes problems associated with microbial and mammalian-cell systems. In particular, production of the proteins should allow large volume production at low cost, and yield properly processed and glycosylated proteins. The production system should also have a relatively stable genotype from generation to generation. These aims are achieved, in the present invention, for the therapeutic proteins AAT, HSA, and antithrombin III (ATIII), and the industrial enzyme subtilisin BPN'.

Human α_1 -antitrypsin

Human α_1 -antitrypsin (AAT) is a monomer with a molecular weight of about 52Kd. Normal AAT contains 394 residues, with three complex oligosaccharide units exposed to the surface of the molecule, linked to asparagines 46, 83, and 247 (Carrell, P., *et al.*, *Nature* (1982) 298:329).

AAT is the major plasma proteinase inhibitor whose primary function is to control the proteolytic activity of trypsin, elastase, and chymotrypsin in plasma. In particular, the protein is a potent inhibitor of neutrophil elastase, and a deficiency of AAT has been observed in a number of patients with chronic emphysema of the lungs. A proportion of individuals with serum deficiency of AAT may progress to cirrhosis and liver failure (*e.g.*, Wu, Y., *et al.*, *BioEssays* 13(4):163 (1991)).

Because of the key role of AAT as an elastase inhibitor, and because of the prevalence of genetic diseases resulting in deficient serum levels of AAT, there has been an active interest in recombinant synthesis of AAT, for human therapeutic use. To date, this approach has not been satisfactory for AAT produced by recombinant methods, for the reasons discussed above.

Human Antithrombin III

Antithrombin III (ATIII) is the major inhibitor of thrombin and factor Xa, and to a lesser extent, other serine proteases generated during the coagulation process, *e.g.*, factors IXa, XIa, and XIIa. The inhibitory effect of ATIII is accelerated dramatically by heparin. In patients with a history of deep vein thrombosis and pulmonary embolism, the prevalence of ATIII deficiency is 2-3%.

ATIII protein has been useful in treating hereditary ATIII deficiency and has wide clinical applications for the prevention of thrombosis in high risk situations, such as surgery and delivery, and for treating acute thrombotic episodes, when used in combination with heparin.

ATIII is a glycoprotein with a molecular weight of 58,200, having 432 amino acids and containing three disulfide linkages and four asparagine-linked biantennary carbohydrate chains. Because of the key role of ATIII as an anti-thrombotic agent, and because of the broad clinical potential in anti-thrombosis therapy, there has been an active interest in recombinant synthesis of ATIII, for human therapeutic use. To date, this approach has not been satisfactory for ATIII produced by microbial or mammalian recombinant methods, for the reasons discussed above.

Human Serum Albumin

Serum albumin is the main protein component of plasma. Its main function is regulation of colloidal osmotic pressure in the bloodstream. Serum albumin binds numerous ions and small molecules, including Ca^{2+} , Na^+ , K^+ , fatty acids, hormones, bilirubin and certain drugs.

Human serum albumin (HSA) is expressed as a 609 amino acid prepro-protein which is further processed by removal of an amino-terminal peptide and an additional six amino acid residues to form the mature protein. The mature protein found in human serum is a monomeric, unglycosylated protein 585 amino acids in length (66 kDal), with a globular structure maintained by 17 disulfide bonds. The pattern of disulfide links forms a structural unit of one small and two large disulfide-linked double loops (Geisow, M.J. *et al.* (1977) *Biochem. J.* 163:477-484) which forms a high-affinity bilirubin binding site.

HSA is used to expand blood volume and raise low blood protein levels in cases of shock, trauma, and post-surgical recovery. HSA is often administered in emergency situations to stabilize blood pressure.

Because of the key role of HSA as an osmotic stabilizing agent, and because of its broad clinical potential in, *e.g.*, plasma replacement therapy, there has been an active interest in recombinant synthesis of HSA for human therapeutic use. This approach has not been satisfactory for HSA produced by microbial or mammalian recombinant methods, for the reasons discussed above.

Subtilisin BPN'

Subtilisin BPN' (BPN') is an important industrial enzyme, particularly for use as a detergent enzyme. Several groups have reported amino acid substitution modifications of the enzyme that are effective in enhancing the activity, pH optimum, stability and/or therapeutic use of the enzyme.

BPN' is expressed in as a 381 amino acid preproenzyme, including 35 amino acid sequence required for secretion and a 77 amino acid moiety which serves as a chaperon to facilitate folding. Studies indicate that the pro moiety acts in trans outside of cells.

To date, large-scale production of BPN' is predominantly by microbial fermentation, which has relatively high costs associated with it. In addition, the enzyme tends to auto-degrade at optimal fermentation growth-medium conditions.

Summary of the Invention

In one aspect, the invention includes a method of producing, in monocot plant cells, a mature heterologous protein selected from the group consisting of (i) mature, glycosylated α_1 -antitrypsin (AAT) having the same N-terminal amino acid sequence as mature AAT produced in humans and a glycosylation pattern which increases serum half-life substantially over that of non-glycosylated mature AAT; (ii) mature, glycosylated antithrombin III (ATIII) having the same N-terminal amino acid sequence as mature ATIII produced in humans; (iii) mature human serum albumin (HSA) having the same N-terminal amino acid sequence as mature HSA produced in

humans and having the folding pattern of native mature HSA as evidenced by its bilirubin-binding characteristics; and (iv) mature, active subtilisin BPN' (BPN'), glycosylated or non-glycosylated, having the same N-terminal amino acid sequence as BPN' produced in *Bacillus*.

The method includes obtaining monocot cells transformed with a chimeric gene having (i) a monocot transcriptional regulatory region, inducible by addition or removal of a small molecule, or during seed maturation, (ii) a first DNA sequence encoding the heterologous protein, and (iii) a second DNA sequence encoding a signal peptide. The second DNA sequence is operably linked to the transcriptional regulatory region and to the first DNA sequence. The first DNA sequence is in translation-frame with the second DNA sequence, and the two sequences encode a fusion protein. The transformed cells are cultivated under conditions effective to induce the transcriptional regulatory region, thereby promoting expression of the fusion protein and secretion of the mature heterologous protein from the transformed cells. The mature heterologous protein produced by the transformed cells is then isolated.

In one embodiment of the method, the first DNA sequence encodes pro-subtilisin BPN' (proBPN'), the cultivating includes cultivating the transformed cells at a pH between 5 and 6, and the isolating step includes incubating the proBPN' to under condition effective to allow its autoconversion to active mature BPN'. In another embodiment, the first DNA sequence encodes mature BPN', and the cells are transformed with a second chimeric gene containing (i) a transcriptional regulatory region inducible by addition or removal of a small molecule, (ii) a third DNA sequence encoding the pro-peptide moiety of BPN', and (iii) a fourth DNA sequence encoding a signal polypeptide. The fourth DNA sequence is operably linked to the transcriptional regulatory region and to the third DNA sequence, and the signal polypeptide is in translation-frame with the pro-peptide moiety and is effective to facilitate secretion of expressed pro-peptide moiety from the transformed cells. The cultivating step includes cultivating the transformed cells at a pH between 5 and 6, and the isolating step includes incubating the mature BPN' and the pro-moiety under conditions effective to allow the conversion of BPN' by the pro- moiety to active mature BPN'.

In another embodiment of the method, the signal peptide is the RAmy3D signal peptide (SEQ ID NO:1) or the RAmy1A signal peptide (SEQ ID NO:4). The coding sequence of the signal peptide may be a codon-optimized sequence, such as the codon-optimized RAmy3D sequence identified as SEQ ID NO:3. The first DNA sequence may also be codon-optimized. Exemplary codon-optimized signal peptide-heterologous protein fusion protein coding sequences include 3D-AAT (SEQ ID NO:18), 3D-ATIII (SEQ ID NO:19), and 3D-HSA (SEQ ID NO:20). The first DNA sequence may further contain codon substitutions which eliminate one or more potential glycosylation sites present in the native amino acid sequence of the heterologous protein, such as the codon-optimized sequence encoding 3D-proBPN' (SEQ ID NO:21).

In other embodiments of the method, the transcriptional regulatory region may be a promoter derived from a rice or barley α -amylase gene, including RAm1A, RAm1B, RAm2A, RAm3A, RAm3B, RAm3C, RAm3D, RAm3E, pM/C, gKAm141, gKAm155, Amy32b, or HV18. The chimeric gene may further include, between the transcriptional regulatory region and the fusion protein coding sequence, the 5' untranslated region (5' UTR) of an inducible monocot gene such as one of the rice or barley α -amylase genes described above. One preferred 5' UTR is that from the RAm1A gene, which is effective to enhance the stability of the gene transcript. The chimeric gene may further include, downstream of the coding sequence, the 3' untranslated region (3' UTR) from an inducible monocot gene, such as one of the rice or barley α -amylase genes mentioned above. One preferred 3' UTR is from the RAm1A gene.

Where the method is employed in protein production in a monocot cell culture, preferred promoters are the RAm3D and RAm3E gene promoters, which are upregulated by sugar depletion in cell culture. Where the gene is employed in protein production in germinating seeds, a preferred promoter is the RAm1A gene promoter, which is upregulated by gibberellic acid during seed germination. Where gene is upregulated during seed maturation, a preferred promoter is the barley endosperm-specific B1-hordein promoter.

The invention also includes a mature heterologous protein produced by the above method. The protein has a glycosylation pattern characteristic of the monocot plant in which the protein is produced. The glycosylated protein is selected from the group consisting of (i) mature glycosylated α_1 -antitrypsin (AAT) having the same N-terminal amino acid sequence as mature AAT produced in humans and having a glycosylation pattern which increases serum half-life substantially over that of non-glycosylated mature AAT; (ii) mature glycosylated antithrombin III (ATIII) having the same N-terminal amino acid sequence as mature ATIII produced in humans; and (iii) mature glycosylated subtilisin BPN' (BPN') having the same N-terminal amino acid sequence as BPN' produced in *Bacillus*.

The invention also includes plant cells and seeds capable of producing the mature heterologous proteins according to the above method.

These and other objects and features of the invention will be more fully understood when the following detailed description of the invention is read in conjunction with the accompanying drawings.

Brief Description of the Figures

Fig. 1 shows, in the lower row, the amino acid sequence of a RAm3D signal sequence portion employed in the invention, identified as SEQ ID NO:1; in the middle row, the corresponding native coding sequence, identified as SEQ ID NO:2; and in the upper row, a corresponding codon-optimized sequence, identified as SEQ ID NO:3;

Fig. 2 illustrates the components of a chimeric gene constructed in accordance with an embodiment of the invention;

Figs. 3A and 3B illustrate the construction of an exemplary transformation vector for use in transforming a monocot plant, for production of a mature protein in cell culture in accordance with one embodiment of the invention (native mature AAT coding sequence under control of the
5 RAm3D promoter and signal sequence);

Fig. 4 illustrates factors in the metabolic regulation of AAT production in rice cell culture;

Fig. 5 shows immunodetection of AAT using antibody raised against the C-terminal region of AAT;

10 Fig. 6 shows Western blot analysis of AAT produced by transformed rice cell lines 18F, 11B, and 27F;

Fig. 7 shows the time course of elastase:AAT complex formation in human and rice-produced forms of AAT;

Fig. 8 shows an N-terminal sequence for mature α_1 -antitrypsin (AAT) produced in
15 accordance with the invention, identified herein as SEQ ID NO:22;

Fig. 9 shows a Western blot of ATIII produced in accordance with the invention;

Fig. 10 shows a Western blot of plant-produced BPN', comparing expression from codon-optimized and native coding sequences;

Fig. 11 compares the specific activity of BPN' codon-optimized (AP106) vs. BPN' native
20 (AP101) expression in rice callus cell culture; and

Fig. 12 shows a western blot of HSA produced in germinating seeds in accordance with the invention.

Brief Description of the Sequences

- 25 SEQ ID NO:1 is the amino acid sequence of the RAm3D signal peptide;
SEQ ID NO:2 is the native sequence encoding the RAm3D signal peptide;
SEQ ID NO:3 is a codon-optimized sequence encoding the RAm3D signal peptide;
SEQ ID NO:4 is the amino acid sequence of the RAm1A signal peptide;
SEQ ID NO:5 is the 5' UTR derived from the RAm1A gene;
30 SEQ ID NO:6 is the 3' UTR derived from the RAm1A gene;
SEQ ID NO:7 is the amino acid sequence of mature α_1 -antitrypsin (AAT);
SEQ ID NO:8 is the native DNA coding sequence of mature AAT;
SEQ ID NO:9 is the amino acid sequence of mature antithrombin III (ATIII);
SEQ ID NO:10 is the native DNA coding sequence of mature ATIII;
35 SEQ ID NO:11 is the amino acid sequence of mature human serum albumin (HSA);

- SEQ ID NO:12 is the native DNA coding sequence of mature HSA;
SEQ ID NO:13 is the amino acid sequence of native proBPN';
SEQ ID NO:14 is the native DNA coding sequence of proBPN';
SEQ ID NO:15 is the amino acid sequence of the "pro" moiety of BPN';
5 SEQ ID NO:16 is the amino acid sequence of native mature BPN';
SEQ ID NO:17 is the amino acid sequence of a mature BPN' variant in which all potential N-glycosylation sites are removed according to Table 2;
SEQ ID NO:18 is a codon-optimized sequence encoding the RAmy3D signal sequence/mature α_1 -antitrypsin fusion protein;
10 SEQ ID NO:19 is a sequence encoding the RAmy3D signal sequence/mature antithrombin III fusion protein, with a codon-optimized RAmy3D coding sequence fused to the native mature ATIII coding sequence;
SEQ ID NO:20 is a sequence encoding the RAmy3D signal sequence/mature human serum albumin fusion protein, with a codon-optimized RAmy3D coding sequence fused to the native
15 mature HSA coding sequence;
SEQ ID NO:21 is a codon-optimized sequence encoding the RAmy3D signal sequence/prosubtilisin BPN' fusion protein;
SEQ ID NO:22 is the N-terminal sequence of mature α_1 -antitrypsin produced in accordance with the invention;
20 SEQ ID NO:23 is an oligonucleotide used to prepare the intermediate p3DProSig construct of Example 1;
SEQ ID NO:24 is the complement of SEQ ID NO:23;
SEQ ID NO:25 is an oligonucleotide used to prepare the intermediate p3DProSigENDlink construct of Example 1;
25 SEQ ID NO:26 is the complement of SEQ ID NO:25;
SEQ ID NO:27 is one of six oligonucleotides used to prepare the intermediate p1AProSig construct of Example 1;
SEQ ID NO:28 is one of six oligonucleotides used to prepare the intermediate p1AProSig construct of Example 1;
30 SEQ ID NO:29 is one of six oligonucleotides used to prepare the intermediate p1AProSig construct of Example 1;
SEQ ID NO:30 is one of six oligonucleotides used to prepare the intermediate p1AProSig construct of Example 1;
SEQ ID NO:31 is one of six oligonucleotides used to prepare the intermediate p1AProSig
35 construct of Example 1;

SEQ ID NO:32 is one of six oligonucleotides used to prepare the intermediate p1AProSig construct of Example 1;

SEQ ID NO:33 is the N-terminal primer used to PCR-amplify the AAT coding sequence according to Example 1; and

5 SEQ ID NO:34 is the C-terminal primer used to PCR-amplify the AAT coding sequence according to Example 1.

Detailed Description of the Invention

I. Definitions:

10 The terms below have the following meaning, unless indicated otherwise in the specification.

"Cell culture" refers to cells and cell clusters, typically callus cells, growing on or suspended in a suitable growth medium.

15 "Germination" refers to the breaking of dormancy in a seed and the resumption of metabolic activity in the seed, including the production of enzymes effective to break down starches in the seed endosperm.

"Inducible" means a promoter that is upregulated by the presence or absence of a small molecules. It includes both indirect and direct inducement.

20 "Inducible during germination" refers to promoters which are substantially silent but not totally silent prior to germination but are turned on substantially (greater than 25%) during germination and development in the seed. Examples of promoters that are inducible during germination are presented below.

25 "Small molecules", in the context of promoter induction, are typically small organic or bioorganic molecules less than about 1 kDal. Examples of such small molecules include sugars, sugar-derivatives (including phosphate derivatives), and plant hormones (such as, gibberellic or abscisic acid).

30 "Specifically regulatable" refers to the ability of a small molecule to preferentially affect transcription from one promoter or group of promoters (e.g., the α -amylase gene family), as opposed to non-specific effects, such as, enhancement or reduction of global transcription within a cell by a small molecule.

35 "Seed maturation" or "grain development" refers to the period starting with fertilization in which metabolizable reserves, e.g., sugars, oligosaccharides, starch, phenolics, amino acids, and proteins, are deposited, with and without vacuole targeting, to various tissues in the seed (grain), e.g., endosperm, testa, aleurone layer, and scutellar epithelium, leading to grain enlargement, grain filling, and ending with grain desiccation.

"Inducible during seed maturation" refers to promoters which are turned on substantially (greater than 25%) during seed maturation.

5 "Heterologous DNA" or "foreign DNA" refers to DNA which has been introduced into plant cells from another source, or which is from a plant source, including the same plant source, but which is under the control of a promoter or terminator that does not normally regulate expression of the heterologous DNA.

"Heterologous protein" is a protein, including a polypeptide, encoded by a heterologous DNA. A "transcription regulatory region" or "promoter" refers to nucleic acid sequences that influence and/or promote initiation of transcription. Promoters are typically considered to include regulatory regions, such as enhancer or inducer elements.

10 A "chimeric gene," in the context of the present invention, typically comprises a promoter sequence operably linked to DNA sequence that encodes a heterologous gene product, *e.g.*, a selectable marker gene or a fusion protein gene. A chimeric gene may also contain further transcription regulatory elements, such as transcription termination signals, as well as translation regulatory signals, such as, termination codons.

"Operably linked" refers to components of a chimeric gene or an expression cassette that function as a unit to express a heterologous protein. For example, a promoter operably linked to a heterologous DNA, which encodes a protein, promotes the production of functional mRNA corresponding to the heterologous DNA.

20 A "product" encoded by a DNA molecule includes, for example, RNA molecules and polypeptides.

"Removal" in the context of a metabolite includes both physical removal as by washing and the depletion of the metabolite through the absorption and metabolizing of the metabolite by the cells.

25 "Substantially isolated" is used in several contexts and typically refers to the at least partial purification of a protein or polypeptide away from unrelated or contaminating components. Methods and procedures for the isolation or purification of proteins or polypeptides are known in the art.

30 "Stably transformed" as used herein refers to a cereal cell or plant that has foreign nucleic acid stably integrated into its genome which is transmitted through multiple generations.

" α_1 -antitrypsin or "AAT" refers to the protease inhibitor which has an amino acid sequence substantially identical or homologous to AAT protein identified by SEQ ID NO:7.

35 "Antithrombin III" or "ATIII" refers to the heparin-activated inhibitor of thrombin and factor Xa, and which has an amino acid sequence substantially identical or homologous to ATIII protein identified by SEQ ID NO:9.

"Human serum albumin" or "HSA" refers to a protein which has an amino acid sequence substantially identical or homologous to the mature HSA protein identified by SEQ ID NO:11.

"Subtilisin" or "subtilisin BPN'" or "BPN'" refers to the protease enzyme produced naturally by *B. amyloliquefaciens*, and having the sequence of SEQ ID NO:16, or a sequence homologous therewith.

"proBPN'" refers to a form of BPN' having an approximately 78 amino-acid "pro" moiety that functions as a chaperon polypeptide to assist in folding and activation of the BPN', and having the sequence in SEQ ID NO:13, or a sequence homologous therewith.

"Codon optimization" refers to changes in the coding sequence of a gene to replace native codons with those corresponding to optimal codons in the host plant.

A DNA sequence is "derived from" a gene, such as a rice or barley α -amylase gene, if it corresponds in sequence to a segment or region of that gene. Segments of genes which may be derived from a gene include the promoter region, the 5' untranslated region, and the 3' untranslated region of the gene.

II. Transformed plant cells

The plants used in the process of the present invention are derived from monocots, particularly the members of the taxonomic family known as the Gramineae. This family includes all members of the grass family of which the edible varieties are known as cereals. The cereals include a wide variety of species such as wheat (*Triticum* spp.), rice (*Oryza* spp.) barley (*Hordeum* spp.) oats, (*Avena* spp.) rye (*Secale* spp.), corn (*Zea* spp.) and millet (*Pennisetum* spp.). In the present invention, preferred family members are rice and barley.

Plant cells or tissues derived from the members of the family are transformed with expression constructs (*i.e.*, plasmid DNA into which the gene of interest has been inserted) using a variety of standard techniques (*e.g.*, electroporation, protoplast fusion or microparticle bombardment). The expression construct includes a transcription regulatory region (promoter) whose transcription is specifically upregulated by the presence of absence of a small molecule, such as the reduction or depletion of sugar, *e.g.*, sucrose, in culture medium, or in plant tissues, *e.g.*, germinating seeds. In the present invention, particle bombardment is the preferred transformation procedure.

The construct also includes a gene encoding a mature heterologous protein in a form suitable for secretion from plant cells. The gene encoding the recombinant heterologous protein is placed under the control of a metabolically regulated promoter. Metabolically regulated promoters are those in which mRNA synthesis or transcription, is repressed or upregulated by a small metabolite or hormone molecule, such as the rice RAmy3D and RAmy3E promoters, which are

upregulated by sugar-depletion in cell culture. For protein production in germinating seeds from regenerated transgenic plants, a preferred promoter is the Ramy 1A promoter, which is up-regulated by gibberellic acid during seed germination. The expression construct also utilizes additional regulatory DNA sequences *e.g.*, preferred codons, termination sequences, to promote efficient translation of AAT, as will be described.

A. Plant Expression Vector

Expression vectors for use in the present invention comprise a chimeric gene (or expression cassette), designed for operation in plants, with companion sequences upstream and downstream from the expression cassette. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from bacteria to the desired plant host. Suitable transformation vectors are described in related application PCT WO 95/14099, published May 25, 1995, which is incorporated by reference herein. Suitable components of the expression vector, including an inducible promoter, coding sequence for a signal peptide, coding sequence for a mature heterologous protein, and suitable termination sequences are discussed below. One exemplary vector is the p3D(AAT)v1.0 vector illustrated in Figs 3A and 3B.

A1. Promoters

The transcription regulatory or promoter region is chosen to be regulated in a manner allowing for induction under selected cultivation conditions, *e.g.*, sugar depletion in culture or water uptake followed by gibberellic acid production in germinating seeds. Suitable promoters, and their method of selection are detailed in above-cited PCT application WO 95/14099. Examples of such promoters include those that transcribe the cereal α -amylase genes and sucrose synthase genes, and are repressed or induced by small molecules, like sugars, sugar depletion or phytohormones such as gibberellic acid or abscisic acid. Representative promoters include the promoters from the rice α -amylase RAmy1A, RAmy1B, RAmy2A, RAmy3A, RAmy3B, RAmy3C, RAmy3D, and RAmy3E genes, and from the pM/C, gKAmy141, gKAmy155, Amy32b, and HV18 barley α -amylase genes. These promoters are described, for example, in ADVANCES IN PLANT BIOTECHNOLOGY Ryu, D.D.Y., *et al*, Eds., Elsevier, Amsterdam, 1994, p.37, and references cited therein. Other suitable promoters include the sucrose synthase and sucrose-6-phosphate-synthetase (SPS) promoters from rice and barley.

Other suitable promoters include promoters which are regulated in a manner allowing for induction under seed-maturation conditions. Examples of such promoters include those associated with the following monocot storage proteins: rice glutelins, oryzins, and prolamines, barley hordeins, wheat gliadins and glutelins, maize zeins and glutelins, oat glutelins, and sorghum

kafirins, millet pennisetins, and rye secalins.

A preferred promoter for expression in germinating seeds is the rice α -amylase RAmy1A promoter, which is upregulated by gibberellic acid. Preferred promoters for expression in cell culture are the rice α -amylase RAmy3D and RAmy3E promoters which are strongly upregulated by sugar depletion in the culture. These promoters are also active during seed germination. A preferred promoter for expression in maturing seeds is the barley endosperm-specific B1-hordein promoter (Brandt, A., *et al.*, (1985) Carlsberg Res. Commun. 50:333-345).

The chimeric gene may further include, between the promoter and coding sequences, the 5' untranslated region (5' UTR) of an inducible monocot gene, such as the 5' UTR derived from one of the rice or barley α -amylase genes mentioned above. One preferred 5' UTR is that derived from the RAmy1A gene, which is effective to enhance the stability of the gene transcript. This 5' UTR has the sequence given by SEQ ID NO:5 herein.

A2. Signal Sequences

In addition to encoding the protein of interest, the chimeric gene encodes a signal sequence (or signal peptide) that allows processing and translocation of the protein, as appropriate. Suitable signal sequences are described in above-referenced PCT application WO 95/14099. One preferred signal sequence is identified as SEQ ID NO:1 and is derived from the RAmy3D promoter. Another preferred signal sequence is identified as SEQ ID NO:4 and is derived from the RAmy1A promoter. The plant signal sequence is placed in frame with a heterologous nucleic acid encoding a mature protein, forming a construct which encodes a fusion protein having an N-terminal region corresponding to the signal peptide and, immediately adjacent to the C-terminal amino acid of the signal peptide, the N-terminal amino acid of the mature heterologous protein. The expressed fusion protein is subsequently secreted and processed by signal peptidase cleavage precisely at the junction of the signal peptide and the mature protein, to yield the mature heterologous protein.

In another embodiment of the invention, the coding sequence in the fusion protein gene, in at least the coding region for the signal sequence, may be codon-optimized for optimal expression in plant cells, *e.g.*, rice cells, as described below. The upper row in Fig. 1 shows one codon-optimized coding sequence for the RAmy3D signal sequence, identified herein as SEQ ID NO:3.

A3. Naturally-Occurring Heterologous Protein Coding Sequences

(i) α_1 -Antitrypsin: Mature human AAT is composed of 394 amino acids, having the sequence identified herein as SEQ ID NO:7. The protein has N-glycosylation sites at asparagines 46, 83 and 247. The corresponding native DNA coding sequence is identified herein as SEQ ID NO:8.

(ii) Antithrombin III: Mature human ATIII is composed of 432 amino acids, having the sequence identified herein as SEQ ID NO:9. The protein has N-glycosylation sites at the four asparagine residues 96, 135, 155, and 192. The corresponding native DNA coding sequence is identified herein as SEQ ID NO:10.

5 (iii) Human serum albumin: Mature HSA as found in human serum is composed of 585 amino acids, having the sequence identified herein as SEQ ID NO:11. The protein has no N-linked glycosylation sites. The corresponding native DNA coding sequence is identified herein as SEQ ID NO:12.

10 (iv) Subtilisin BPN': Native proBPN' as produced in *B. amyloliquefaciens* is composed of 352 amino acids, having the sequence identified herein as SEQ ID NO:13. The corresponding native DNA coding sequence is identified herein as SEQ ID NO:14. The proBPN' polypeptide contains a 77 amino acid "pro" moiety which is identified herein as SEQ ID NO:15. The remainder of the polypeptide, which forms the mature active BPN', is a 275 amino acid sequence identified herein by SEQ ID NO:16. Native BPN' as produced in *Bacillus* is not glycosylated.

15 A4. Codon-Optimized Coding Sequences

In accordance with one aspect of the invention, it has been discovered that a severalfold enhancement of expression level can be achieved in plant cell culture by modifying the native coding sequence of a heterologous gene by contain predominantly or exclusively, highest-frequency codons found in the plant cell host.

20 The method will be illustrated for expression of a heterologous gene in rice plant cells, it being recognized that the method is generally applicable to any monocot. As a first step, a representative set of known coding gene sequence from rice is assembled. The sequences are then analyzed for codon frequency for each amino acid, and the most frequent codon is selected for each amino acid. This approach differs from earlier reported codon matching methods, in which more than one frequent codon is selected for at least some of the amino acids. The optimal codons selected in this manner for rice and barley are shown in Table 1.

Table 1

| Amino Acid | Rice Preferred Codon | Barley Preferred Codon |
|------------|----------------------|------------------------|
| Ala A | GCC | |
| Arg R | CGC | |
| Asn N | AAC | |

| Amino Acid | Rice Preferred Codon | Barley Preferred Codon |
|------------|----------------------|------------------------|
| Asp D | GAC | |
| Cys C | UGC | |
| Gln Q | CAG | |
| Glu E | GAG | |
| Gly G | GGC | |
| His H | CAC | |
| Ile I | AUC | |
| Leu L | CUC | |
| Lys K | AAG | |
| Phe F | UUC | |
| Pro P | CCG | CCC |
| Ser S | AGC | UCC |
| Thr T | ACC | |
| Tyr Y | UAC | |
| Val V | GUC | GUG |
| stop | UAA | UGA |

As indicated above, the fusion protein coding sequence in the chimeric gene is constructed such that the final (C-terminal) codon in the signal sequence is immediately followed by the codon for the N-terminal amino acid in the mature form of the heterologous protein. Exemplary fusion protein genes, in accordance with the present invention, are identified herein as follows:

SEQ ID NO:18, corresponding to codon-optimized coding sequences of the fusion protein consisting of RAmy3D signal sequence/mature α_1 -antitrypsin;

SEQ ID NO:19, corresponding to the fusion protein coding sequence consisting of the codon-optimized RAmy3D signal sequence and the native mature antithrombin III sequence;

SEQ ID NO:20, corresponding to the fusion protein coding sequence consisting of the codon-optimized RAmy3D signal sequence and the native mature human serum albumin sequence;

SEQ ID NO:21, corresponding to codon-optimized coding sequence of the fusion protein RAmy3D signal sequence/prosubtilisin BPN'. In this instance, prosubtilisin is considered the "mature" protein, in that secreted prosubtilisin can autocatalyze to active, mature subtilisin.

In a preferred embodiment, the BPN' coding sequence is further modified to eliminate

potential N-glycosylation sites, as native BPN' is not glycosylated. Table 2 illustrates preferred codon substitutions, which eliminate all potential N-glycosylation sites in subtilisin BPN'. SEQ ID NO:17 corresponds to a mature BPN' amino acid sequence containing the substitutions presented in Table 2.

5

Table 2

| N-Glycosylation Sites | Location (Asn) (in mature protein) | Amino Acid Substitution |
|-----------------------|------------------------------------|--------------------------|
| Asn Asn Ser | 61 | Thr Asn Ser |
| Asn Asn Ser | 76 | Thr Asn Ser |
| Asn Met Ser | 123 | Thr Met Ser |
| Asn Gly Thr | 218 | Ser Gly Thr ¹ |
| Asn Trp Thr | 240 | Thr Trp Thr |

¹improved thermostability; Bryan, *et al.*, *Proteins: Structure, Function, and Genetics* 1:326 (1986).

10

A5. Transcription and Translation Terminators

The chimeric gene may also include, downstream of the coding sequence, the 3' untranslated region (3' UTR) from an inducible monocot gene, such as one of the rice or barley α -amylase genes mentioned above. One preferred 3' UTR is that derived from the RAmy1A gene, whose sequence is given by SEQ ID NO:6. This sequence includes non-coding sequence 5' to the polyadenylation site, the polyadenylation site, and the transcription termination sequence. The transcriptional termination region may be selected, particularly for stability of the mRNA to enhance expression. Polyadenylation tails (Alber and Kawasaki, 1982, *Mol. and Appl. Genet.* 1:419-434) are also commonly added to the expression cassette to optimize high levels of transcription and proper transcription termination, respectively. Polyadenylation sequences include but are not limited to the *Agrobacterium* octopine synthetase signal (Gielen, *et al.*, *EMBO J.* 3:835-846 (1984) or the nopaline synthase of the same species (Depicker, *et al.*, *Mol. Appl. Genet.* 1:561-573 (1982).

Since the ultimate expression of the heterologous protein will be in a eukaryotic cell (in this case, a member of the grass family), it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicing machinery. If so, site-directed mutagenesis of the "intron" region may be conducted to prevent losing a portion of the genetic message as a false intron code (Reed and Maniatis, *Cell* 41:95-105 (1985).

15

Fig. 2 shows the elements of one preferred chimeric gene constructed in accordance with the invention, and intended particularly for use in protein expression in a rice cell suspension culture. The gene includes, in a 5' to 3' direction, the promoter from the RAmv3D gene, which is inducible in cell culture with sugar depletion, the 5' UTR from the RAmv1A gene, which confers enhanced stability on the gene transcript, the RAmv3D signal sequence coding region, as identified above, the coding region of a heterologous protein to be produced, and a 3' UTR region from the RAmv1A gene.

III. Plant Transformation

For transformation of plants, the chimeric gene is placed in a suitable expression vector designed for operation in plants. The vector includes suitable elements of plasmid or viral origin that provide necessary characteristics to the vector to permit the vectors to move DNA from bacteria to the desired plant host. Suitable transformation vectors are described in related application PCT WO 95/14099, published May 25, 1995, which is incorporated by reference herein. Suitable components of the expression vector, including the chimeric gene described above, are discussed below. One exemplary vector is the p3Dv1.0 vector described in Example 1.

A. Transformation Vector

Vectors containing a chimeric gene of the present invention may also include selectable markers for use in plant cells (such as the *nptII* kanamycin resistance gene, for selection in kanamycin-containing or the phosphinothricin acetyltransferase gene, for selection in medium containing phosphinothricin (PPT)).

The vectors may also include sequences that allow their selection and propagation in a secondary host, such as sequences containing an origin of replication and a selectable marker such as antibiotic or herbicide resistance genes, *e.g.*, HPH (Hagio *et al.*, *Plant Cell Reports* 14:329 (1995); van der Elzer, *Plant Mol. Biol.* 5:299-302 (1985). Typical secondary hosts include bacteria and yeast. In one embodiment, the secondary host is *Escherichia coli*, the origin of replication is a *colE1*-type, and the selectable marker is a gene encoding ampicillin resistance. Such sequences are well known in the art and are commercially available as well (*e.g.*, Clontech, Palo Alto, CA; Stratagene, La Jolla, CA).

The vectors of the present invention may also be modified to intermediate plant transformation plasmids that contain a region of homology to an *Agrobacterium tumefaciens* vector, a T-DNA border region from *Agrobacterium tumefaciens*, and chimeric genes or expression cassettes (described above). Further, the vectors of the invention may comprise a disarmed plant tumor inducing plasmid of *Agrobacterium tumefaciens*.

The vector described in Example 1, and having a promoter from the RAmy3D gene, is suitable for use in a method of mature protein production in cell culture, where the RAmy3D promoter is induced by sugar depletion in cell culture medium. Other promoters may be selected for other applications, as indicated above. For example, for mature protein expression in germinating seeds, the coding sequence may be placed under the control of the rice α -amylase RAmy1A promoter, which is inducible by gibberellic acid during seed germination.

B. Transformation of plant cells

Various methods for direct or vectored transformation of plant cells, *e.g.*, plant protoplast cells, have been described, *e.g.*, in above-cited PCT application WO 95/14099. As noted in that reference, promoters directing expression of selectable markers used for plant transformation (*e.g.*, nptII) should operate effectively in plant hosts. One such promoter is the nos promoter from native Ti plasmids (Herrera-Estrella, *et al.*, *Nature* 303:209-213 (1983). Others include the 35S and 19S promoters of cauliflower mosaic virus (Odell, *et al.*, *Nature* 313:810-812 (1985) and the 2' promoter (Velten, *et al.*, *EMBO J.* 3:2723-2730 (1984).

In one preferred embodiment, the embryo and endosperm of mature seeds are removed to exposed scutulum tissue cells. The cells may be transformed by DNA bombardment or injection, or by vectored transformation, *e.g.*, by *Agrobacterium* infection after bombarding the scuteller cells with microparticles to make them susceptible to *Agrobacterium* infection (Bidney *et al.*, *Plant Mol. Biol.* 18:301-313, 1992).

One preferred transformation follows the methods detailed generally in Sivamani, E. *et al.*, *Plant Cell Reports* 15:465 (1996); Zhang, S., *et al.*, *Plant Cell Reports* 15:465 (1996); and Li, L., *et al.*, *Plant Cell Reports* 12:250 (1993). Briefly, rice seeds are sterilized by standard methods, and callus induction from the seeds is carried out on MB media with 2,4D. During a first incubation period, callus tissue forms around the embryo of the seed. By the end of the incubation period, (*e.g.*, 14 days at 28°C) the calli are about 0.25 to 0.5 cm in diameter. Callus mass is then detached from the seed, and placed on fresh NB media, and incubated again for about 14 days at 28°C. After the second incubation period, satellite calli developed around the original "mother" callus mass. These satellite calli were slightly smaller, more compact and defined than the original tissue. It was these calli were transferred to fresh media. The "mother" calli was not transferred. The goal was to select only the strongest, most vigorous growing tissue for further culture.

Calli to be bombarded are selected from 14-day-old subcultures. The size, shape, color and density are all important in selecting calli in the optimal physiological condition for transformation. The calli should be between .8 and 1.1 mm in diameter. The calli should appear as spherical masses with a rough exterior.

Transformation is by particle bombardment, as detailed in the references cited above. After the transformation steps, the cells are typically grown under conditions that permit expression of the selectable marker gene. In a preferred embodiment, the selectable marker gene is HPH. It is preferred to culture the transformed cells under multiple rounds of selection to produce a uniformly stable transformed cell line.

IV. Cell Culture Production of Mature Heterologous Protein

Transgenic cells, typically callus cells, are cultured under conditions that favor plant cell growth, until the cells reach a desired cell density, then under conditions that favor expression of the mature protein under the control of the given promoter. Preferred culture conditions are described below and in Example 2. Purification of the mature protein secreted into the medium is by standard techniques known by those of skill in the art.

Production of mature AAT: In a preferred embodiment, the culture medium contains a phosphate buffer, e.g., the 20 mM phosphate buffer, pH 6.8 described in Example 2, to reduce AAT degradation catalyzed by metals. Alternatively, or in addition, a metal chelating agent, such as EDTA, may be added to the medium.

Following the cell culture method described in Example 2, cell culture media was partially purified and the fraction containing AAT was analyzed by Western blot, as shown in Fig. 4. The first two lanes ("phosphate") show AAT bands both in the presence and absence of elastase (" +E" and "-E"), where the higher molecular weight bands in the presence of elastase correspond roughly to a 58-59 kdal AAT/elastase complex. Also as seen in the figure, expression was high in the absence of sucrose, but nearly undetectable in the presence of sucrose.

To ascertain the degree of glycosylation (as determined by apparent molecular weight by SDS-PAGE) the protein produced in culture was fractionated by SDS-PAGE and immunodetected with a labeled antibody raised against the C-terminal portion of AAT, as shown in Fig. 5. Lane 4 contains human AAT, and its migration position corresponds to about 52 kdal. In lane 3 is the plant-produced AAT, having an apparent molecular weight of about 49-50 kdal, indicating an extent of glycosylation of up to 60-80% of the glycosylation found in human AAT (non-glycosylated AAT has a molecular weight of 45 kdal).

Similar results are shown in the Western blots in Fig. 6. Lanes 1-3 in this figure correspond to decreasing amount (15, 10, and 5 ng) of human AAT; lane 4, to 10 μ l supernatant from a non-expressing plant cell line; lanes 5 and 6, to 10 μ l supernatant from AAT-expressing plant cell lines 11B and 27F, respectively, and lane 7, to 10 μ l supernatant from cell line 27F plus 250 ng trypsin. The upward mobility shift in lane 7 is indicative of association between trypsin and the plant-produced AAT.

The ability of plant-produced AAT to bind to elastase is demonstrated in Fig. 7, which shows the shift in molecular weight over a 30 minute binding interval for the 52 kdal human AAT (lanes 1-4) and the 49-50 kdal plant-produced AAT.

To demonstrate that the mature protein is produced in secreted form, with the desired N-terminus, a chimeric gene constructed as above, and having the coding sequence for mature α_1 -antitrypsin was expressed and secreted in cell culture as described in Example 2. The isolated protein was then sequenced at its N-terminal region, yielding the N-terminal sequence shown in Fig. 8. This sequence, which is identified herein as SEQ ID NO:22, has the same N-terminal residues as native mature α_1 -antitrypsin.

Production of mature ATIII: In a preferred embodiment, the culture medium contains a MES buffer, pH 6.8. Western blot analysis of the ATIII protein produced, shown in lanes 4 and 6 in Fig. 9, shows a band corresponding to ATIII (lane 1) in cell lines 42 and 46, when grown in the absence (but not in the presence) of sucrose.

Production of mature BPN': In one embodiment of the invention, in which BPN' is secreted as the proBPN' form of the enzyme, the chaperon "pro" moiety of the enzyme facilitates enzyme folding and is cleaved from the enzyme, leaving the active mature form of BPN'. In another embodiment, the mature enzyme is co-expressed and co-secreted with the "pro" chaperon moiety, with conversion of the enzyme to active form occurring in presence of the free chaperon (Eder *et al.*, *Biochem.* (1993) 32:18-26; Eder *et al.*, (1993) *J. Mol. Biol.* 223:293-304). In yet another embodiment of the invention, the BPN' is secreted in inactive form at a pH that may be in the 6-8 range, with subsequent activation of the inactive form, *e.g.*, after enzyme isolation, by exposure to the "pro" chaperon moiety, *e.g.*, immobilized to a solid support.

In both of these embodiments, the culture medium is maintained at a pH of between 5 and 6, preferably about 5.5 during the period of active expression and secretion of BPN', to keep the BPN', which is normally active at alkaline pH, at a pH below optimal activity.

Codon optimization to the host plant's most frequent codons yielded a severalfold enhancement in the level of expressed heterologous protein in cell culture as shown in Fig. 11. The extent of enhancement is seen from the Western blot analysis shown in Fig. 10 for two cells lines and further substantiated in Fig. 11. Lane 2 (second from left) in Fig. 10 shows a Western blot of BPN' obtained in culture from cells transformed with a native proBPN' coding sequence. Two bands observed correspond to a lower molecular weight protein whose approximately 35 kdal molecular weight corresponds to that of proBPN'. The upper band corresponds to a somewhat higher molecular weight species, possibly glycosylated.

The first lane in the figure shows BPN' polypeptides produced in culture by plant cells transformed with the codon-optimized proBPN' sequence identified by SEQ ID NO:21. For

comparative purposes, the same volume of culture medium, adjusted for cell density, was applied in both lanes 1 and 2. As seen, the amount of BPN' enzyme produced with a codon-optimized sequence was severalfold higher than for subtilisin BPN' produced with the native coding sequence.

Further, a dark band or bands corresponding to mature peptide (molecular weight 27.5 kdal) was observed. However, it should be noted that directly above the band at 35kD is a more pronounced band which may be pro mature product yet to be cleaved into active form.

Fig. 11 compares the specific activity of BPN' codon-optimized (AP106) versus BPN' native (AP101) expression in rice callus cell culture, assayed using the chromogenic peptide substrate suc-Ala-Ala-Pro-Phe-pNA as described by DelMar, E.G. *et al.* (1979; Anal. Biochem. 99:316-320). As shown in Fig. 11, several of the cell lines transformed with codon-optimized chimeric genes produced levels of BPN', as evidenced by measured specific activity in culture medium, that were 2-5 times the highest levels observed for plant cells transformed with native proBPN' sequence.

In accordance with another aspect of the invention, it has been found that the transformed plant cell culture is able to express and secrete BPN' at a cell culture pH, pH 5.5, which largely inhibits self-degradation of mature, active BPN'. To assay for optimal pH conditions, the assay disclosed in DelMar, *et al.* (*supra*) is used to test the media derived from BPN' transformed cell lines under various pH conditions. Transformed rice callus cells are cultured in a MES medium under similar conditions as disclosed in Example 2, but where the pH of the medium is maintained at a selected pH between 5 and 8.0. At each pH, the total amount of expressed and secreted BPN' is determined by Western blot analysis. BPN' activity can be tested in the assay described by DelMar (*supra*).

V. Production of Mature Heterologous Protein in Germinating Seeds

In this embodiment, monocot cells transformed as above are used to regenerate plants, seeds from the plants are harvested and then germinated, and the mature protein is isolated from the germinated seeds.

Plant regeneration from cultured protoplasts or callus tissue is carried by standard methods, *e.g.*, as described in Evans *et al.*, HANDBOOK OF PLANT CELL CULTURES Vol. 1: (MacMillan Publishing Co. New York, 1983); and Vasil I.R. (ed.), CELL CULTURE AND SOMATIC CELL GENETICS OF PLANTS, Acad. Press, Orlando, Vol. I, 1984, and Vol. III, 1986, and as described in the above-cited PCT application.

A. Seed Germination Conditions

The transgenic seeds obtained from the regenerated plants are harvested, and prepared for germination by an initial steeping step, in which the seeds immersed in or sprayed with water to

increase the moisture content of the seed to between 35-45%. This initiates germination. Steeping typically takes place in a steep tank which is typically fitted with a conical end to allow the seed to flow freely out. The addition of compressed air to oxygenate the steeping process is an option. The temperature is controlled at approximately 22°C depending on the seed.

- 5 After steeping, the seeds are transferred to a germination compartment which contains air saturated with water and is under controlled temperature and air flows. The typical temperatures are between 12-25°C and germination is permitted to continue for from 3 to 7 days.

Where the heterologous protein coding gene is operably linked to a inducible promoter requiring a metabolite such as sugar or plant hormone, *e.g.*, 2 to 100 μ M gibberellic acid, this
10 metabolite is added, removed or depleted from the steeping water medium and/or is added to the water saturated air used during germination. The seed absorbs the aqueous medium and begins to germinate, expressing the heterologous protein. The medium may then be withdrawn and the malting begun, by maintaining the seeds in a moist temperature controlled aerated environment. In this way, the seeds may begin growth prior to expression, so that the expressed product is less
15 likely to be partially degraded or denatured during the process.

More specifically, the temperature during the imbibition or steeping phase will be maintained in the range of about 15-25°C, while the temperature during the germination will usually be about 20°C. The time for the imbibition will usually be from about 1 to 4 days, while the germination time will usually be an additional 1 to 10 days, more usually 3 to 7 days. Usually, the
20 time for the malting does not exceed about ten days. The period for the malting can be reduced by using plant hormones during the imbibition, particularly gibberellic acid.

To achieve maximum production of recombinant protein from malting, the malting procedure may be modified to accommodate de-hulled and de-embryonated seeds, as described in above-cited PCT application WO 95/14099. In the absence of sugars from the endosperm, there is
25 expected to be a 5 to 10 fold increase in RAmy3D promoter activity and thus expression of heterologous protein. Alternatively when embryoless half-seeds are incubated in 10 mM CaCl₂ and 5 μ M gibberellic acid, there is a 50 fold increase in RAmy1A promoter activity.

Production of mature HSA: Following the germination conditions as outlined above and further detailed in Example 3, supernatant was analyzed by Western blot. Western blot analysis
30 shows production of HSA in germinating rice seeds, with seed samples taken 24, 72, and 120 hours after induction with gibberellin. HSA production was highest approximately 24 hours post-induction (lanes 3 and 4, Fig. 12). Bilirubin binding, a measure of correct folding of plant-produced HSA, is assayed according to the method presented in Example 3.

35 VI. Production of Mature Heterologous Protein in Maturing Seeds

In this embodiment, monocot cells transformed as above are used to regenerate plants, and seeds from the plants are allowed to mature, typically in the field, with consequent production of heterologous protein in the seeds.

Following seed maturation, the seeds and their heterologous proteins may be used directly, that is, without protein isolation, where for example, the heterologous protein is intended to confer a benefit on the seed as a whole, for example, to enrich the seed in the selected protein.

Alternatively, the seeds may be fractionated by standard methods to obtain the heterologous protein in enriched or purified form. In one general approach, the seed is first milled, then suspended in a suitable extraction medium, e.g., an aqueous or an organic solvent, to extract the protein or metabolite of interest. If desired the heterologous protein can be further fractionated and purified, using standard purification methods.

The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of noncritical parameters which could be changed or modified to yield essentially similar results.

General Methods

Generally, the nomenclature and laboratory procedures with respect to standard recombinant DNA technology can be found in Sambrook, *et al.*, MOLECULAR CLONING - A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1989 and in S.B. Gelvin and R.A. Schilperoot, PLANT MOLECULAR BIOLOGY, 1988. Other general references are provided throughout this document. The procedures therein are known in the art and are provided for the convenience of the reader.

Example 1

Construction of a Transforming Vector Containing a Codon-Optimized α_1 -antitrypsin Sequence

A. Hygromycin Resistance Gene Insertion:

The 3 kb *Bam*HI fragment containing the 35S promoter-Hph-NOS was removed from the plasmid pMON410 (Monsanto, St. Louis, MO) and placed into an site-directed mutagenized *Bgl*II site in the pUC18 at 1463 to form the plasmid pUCH18+.

B. Terminator Insertion:

pOSg1ABK5 is a 5 kb *Bam*HI-*Kpn*I fragment from lambda clone λ OSg1A (Huang, N., *et al.*, (1990) Nuc. Acids Res. 18:7007) cloned into pBluescript KS- (Stratagene, San Diego, CA).

Plasmid pOSg1ABK5 was digested with *MspI* and blunted with T4 DNA polymerase followed by *SpeI* digestion. The 350 bp terminator fragment was subcloned into pUC19 (New England BioLabs, Beverly, MA), which had been digested with *BamHI*, blunted with T4 DNA polymerase and digested with *XbaI*, to form pUC19/terminator.

5

C. RAmy3D Promoter Insertion:

A 1.1 kb *NheI-PstI* fragment derived from p1AS1.5 (Huang, N. *et al.* (1993) Plant Mol. Biol. 23:737-747), was cloned into the vector pGEM5zf- [multiple cloning site (MCS) (Promega, Madison, WI): *ApaI*, *AatII*, *SphI*, *NcoI*, *SstII*, *EcoRV*, *SpeI*, *NofI*, *PstI*, *SalI*, *NdeI*, *SacI*, *MluI*, *NsiI*] at the *SpeI* and *PstI* sites to form pGEM5zf-(3D/*NheI-PstI*). pGEM5zf-(3D/*NheI-PstI*) was then digested with *PstI* and *SacI*, and two non-kinased 30mers having the complementary sequences 5' GCTTG ACCTG TAACT CGGGC CAGGC GAGCT 3' (SEQ ID NO:23) and 5' CGCCT AGCCC GAGTT ACAGG TCAAG CAGCT 3' (SEQ ID NO:24) were ligated in to form p3DProSig. The promoter fragment prepared by digesting p3DProSig with *NcoI*, blunting with T4 DNA polymerase, and digesting with *SstI* was subcloned into pUC19/terminator which had been digested with *EcoRI*, blunted with T4 DNA polymerase and digested with *SstI*, to form p3DProSigEND.

10

15

D. Multiple Cloning Site Insertion:

p3DProSigEND was digested with *SstI* and *SmaI* followed by the ligation of a new synthetic linker fragment constructed with the non-kinased complementary oligonucleotides 5' AGCTC CATGG CCGTG GCTCG AGTCT AGACG CGTCC CC 3' (SEQ ID NO:25) and 5' GGGGA CGCGT CTAGA CTCGA GCCAC GGCCA TGG 3' (SEQ ID NO:26) to form p3DProSigENDlink.

20

25

E. p3DProSigENDlink Flanking Site Modification:

p3DProSigENDlink was digested with *SalI* and blunted with T4 DNA polymerase followed by *EcoRV* digestion. The blunt fragment was then inserted into pBluescript KS+ (Stratagene) in the *EcoRV* site so that the *HindIII* site is proximal to the promoter and the *EcoRI* is proximal to the terminator sequence. The *HindIII-EcoRI* fragment was then moved into the polylinker of pUCH18+ to form the p3Dv1.0 expression vector.

30

F. RAmy1A Promoter Insertion:

A 1.9 kb *NheI-PstI* fragment derived from subclone pOSG2CA2.3 from lambda clone λ OSg2 (Huang *et al.* (1990) Plant Mol. Biol. 14:655-668), was cloned into the vector pGEM5zf- at

35

the *SpeI* and *PstI* sites to form pGEM5zf-(1A/*NheI*-*PstI*). pGEM5zf-(1A/*NheI*-*PstI*) was digested with *PstI* and *SacI* and two non-kinased 35mers and four kinased 32mers were ligated in, with the complementary sequences as follows: 5' GCATG CAGGT GCTGA ACACC ATGGT GAACA AACAC 3' (SEQ ID NO:27); 5' TTCTT GTCCC TTTCG GTCCT CATCG TCCTC CT 3' (SEQ ID NO:28); 5' TGGCC TCTCC TCCAA CTTGA CAGCC GGGAG CT 3' (SEQ ID NO:29); 5' TTCAC CATGG TGTTC AGCAC CTGCA TGCTG CA 3' (SEQ ID NO:30); 5' CGATG AGGAC CGAAA GGGAC AAGAA GTGTT TG 3' (SEQ ID NO:31); 5' CCCGG CTGTC AAGTT GGAGG AGAGG CCAAG GAGGA 3' (SEQ ID NO:32) to form p1AProSig. The *HindIII*-*SacI* 0.8 kb promoter fragment was subcloned from p1AProSig into the p3Dv1.0 vector digested with *HindIII*-*SacI* to yield the p1Av1.0 expression vector.

G. Construction of p3D-AAT Plasmid

Two PCR primers were used to amplify a fragment encoding AAT according to the sequence disclosed as Genbank Accession No. K01396: N-terminal primer 5' GAGGA TCCCC AGGGA GATGC TGCCC AGAA 3' (SEQ ID NO:33) and C-terminal primer 5' CGCGC TCGAG TTATT TTTGG GTGGG ATTCA CCAC 3' (SEQ ID NO:34). The N-terminal primer amplifies to a blunt site for in-frame insertion with the end of the p3D signal peptide and the C-terminal primer contains a *XhoI* site for cloning the fragment into the vector as shown in Figs. 3A and 3B. Alternatively, the sequence encoding mature AAT (SEQ ID NO:8) or codon-optimized AAT may be chemically synthesized using techniques known in the art, incorporating a *XhoI* restriction site 3' of the termination codon for insertion into the expression vector as described above.

Example 2

Production of mature α -antitrypsin in cell culture

After selection of transgenic callus, callus cells were suspended in liquid culture containing AA2 media (Thompson, J.A., *et al.*, *Plant Science* 47:123 (1986), at 3% sucrose, pH 5.8. Thereafter, the cells were shifted to phosphate-buffered media (20 mM phosphate buffer, pH 6.8) using 10 mL multi-well tissue culture plates and shaken at 120 rpm in the dark for 48 hours. The supernatant was then removed and stored at -80°C prior to western blot analysis.

Supernatants were concentrated using Centricon-10 filters (Amicon cat. #4207) and washed with induction media to remove substances interfering with electrophoretic migration. Samples were concentrated approximately 10 fold, and mature AAT was purified by SDS PAGE electrophoresis. The purified protein was extracted from the electrophoresis medium, and sequenced at its N-terminus, giving the sequence shown in Fig. 8, identified herein as SEQ ID NO:22.

Example 3

HSA Induction in Germinating Seeds

5 After selection of transgenic plants which tested positive for the presence of a codon-optimized HSA gene driven by the GA₃-responsive RAmy1A promoter, seeds were harvested and imbibed for 24 hours with 100 rpm orbital shaking in the dark at 25°C. GA₃ was added to a final concentration of 5 μM and incubated for an additional 24-120 hours. Total soluble protein was isolated by double grinding each seed in 120 μl grinding buffer and centrifuging at 23,000 x g for 1
10 minute at 4°C. The clear supernatant was carefully removed from the pellet and transferred to a fresh tube.

Bilirubin binding assay

 Bilirubin binding to its high-affinity site on mature HSA is assayed using the method described by Jacobsen, J. *et al.* (1974; Clin. Chem. 20:783) and Reed, R.G. *et al.* (1975;
15 Biochemistry 14:4578-4583). Briefly, the concentration of free bilirubin in equilibrium with protein-bound bilirubin is determined by the rate of peroxide-peroxidase catalyzed oxidation of free bilirubin. Stock solutions of bilirubin (Nutritional Biochemicals Corp.) are prepared fresh daily in 5 mM NaOH containing 1mM EDTA and the concentration determined using a molar absorptivity of 47,500 M⁻¹ cm⁻¹ at 440 nm. An aliquot containing between 5 and 30 nmol bilirubin is added to a
20 1 cm cuvette containing 1 ml PBS and approximately 30 nmol HSA at 37°C. An absorbance spectrum between 500 and 350 nm is recorded. Aliquots of horseradish peroxidase (Sigma), 0.05 mg/ml in PBS, and 0.05% ethyl hydrogen peroxide (Ferrosan; Malmö Sweden) are added and the change in absorbance at λ_{max} is recorded for 3-5 minutes. The concentrations of free and bound bilirubin calculated from the oxidation rate observed using varying concentrations of total bilirubin
25 are used to construct a Scatchard plot from which the association constant for a single binding site is determined.

 Although the invention has been described with reference to particular embodiments, it will be appreciated that a variety of changes and modifications can be made without departing from the invention.

SEQUENCE LISTING

5 (1) GENERAL INFORMATION

(i) APPLICANT: Applied Phytologics, Inc.

10 (ii) TITLE OF THE INVENTION: Production of Mature Proteins
in Plants

(iii) NUMBER OF SEQUENCES: 34

(iv) CORRESPONDENCE ADDRESS:

15 (A) ADDRESSEE: Dehlinger & Associates
(B) STREET: P.O. Box 60850
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
20 (F) ZIP: 94306

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
25 (C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US98/03068
30 (B) FILING DATE: 13-FEB-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 60/038,169
35 (B) FILING DATE: 13-FEB-1997

(A) APPLICATION NUMBER: 60/037,991
(B) FILING DATE: 13-FEB-1997

40 (A) APPLICATION NUMBER: 60/038,170
(B) FILING DATE: 13-FEB-1997

(A) APPLICATION NUMBER: 60/038,168
45 (B) FILING DATE: 13-FEB-1997

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Petithory, Joanne R
(B) REGISTRATION NUMBER: P42,995
50 (C) REFERENCE/DOCKET NUMBER: 0665-0007.41

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650-324-0880
(B) TELEFAX: 650-324-0960

55 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids
60 (B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

65 (B) CLONE: 3D signal peptide sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Lys Asn Thr Ser Ser Leu Cys Leu Leu Leu Val Val Leu Cys
 1 5 10 15
 Ser Leu Thr Cys Asn Ser Gly Gln Ala
 20 25

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 75 base pairs
 10 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (vii) IMMEDIATE SOURCE:
 15 (B) CLONE: native 3D signal peptide DNA sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
 20 ATGAAGAACA CCAGCAGCTT GTGTTTGCTG CTCCTCGTGG TGCTCTGCAG CTTGACCTGT 60
 AACTCGGGCC AGGCG 75

(2) INFORMATION FOR SEQ ID NO:3:
 (i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 75 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (vii) IMMEDIATE SOURCE:
 30 (B) CLONE: codon-optimized 3D signal peptide DNA sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
 35 ATGAAGAACA CCTCCTCCCT CTGCCTCCTG CTGCTCGTGG TCCTCTGCTC CCTGACCTGC 60
 AACAGCGGCC AGGCC 75

(2) INFORMATION FOR SEQ ID NO:4:
 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 45 (ii) MOLECULE TYPE: peptide
 (vii) IMMEDIATE SOURCE:
 (B) CLONE: RAmylA signal peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

50 Met Val Asn Lys His Phe Leu Ser Leu Ser Val Leu Ile Val Leu Leu
 1 5 10 15
 Gly Leu Ser Ser Asn Leu Thr Ala Gly
 20 25

55 (2) INFORMATION FOR SEQ ID NO:5:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 base pairs
 60 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (vii) IMMEDIATE SOURCE:
 65 (B) CLONE: RAmyl 1A 5' untranslated region (UTR)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATCAATCATC CATCTCCGAA GTGTGTCTGC AGCATGCAGG TGCTGAACAC C

51

(2) INFORMATION FOR SEQ ID NO:6:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 321 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 10 (vii) IMMEDIATE SOURCE:
 (B) CLONE: Ramy 1A 3' untranslated region (UTR)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

15 GCGCAGGATG ACGAGACTCT CAGTTTAGCA GATTTAACCT GCGATTTTTTA CCCTGACCGG 60
 TATACGTATA TACGTGCCGG CAACGAGCTG TATCCGATCC GAATTACGGA TGCAATTGTC 120
 CACGAAGTAC TTCCTCCGTA AATAAAGTAG GATCAGGGAC ATACATTTGT ATGGTTTTAC 180
 GAATAATGCT ATGCAATAAA ATTTGCACTG CTTAATGCTT ATGCATTTTT GCTTGGTTTCG 240
 20 ATTGTACTGG TGAATTATTG TTAGTGTCT TTTTACTTCT CGAGTGGCAG TATTGTTCTT 300
 CTACGAAAAT TTGATGCGTA G 321

(2) INFORMATION FOR SEQ ID NO:7:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 394 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: protein
 (vii) IMMEDIATE SOURCE:
 (B) CLONE: mature AAT amino acid sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

35 Glu Asp Pro Gln Gly Asp Ala Ala Gln Lys Thr Asp Thr Ser His His
 1 5 10 15
 Asp Gln Asp His Pro Thr Phe Asn Lys Ile Thr Pro Asn Leu Ala Glu
 20 25 30
 40 Phe Ala Phe Ser Leu Tyr Arg Gln Leu Ala His Gln Ser Asn Ser Thr
 35 40 45
 Asn Ile Phe Phe Ser Pro Val Ser Ile Ala Thr Ala Phe Ala Met Leu
 50 55 60
 45 Ser Leu Gly Thr Lys Ala Asp Thr His Asp Glu Ile Leu Glu Gly Leu
 65 70 75 80
 Asn Phe Asn Leu Thr Glu Ile Pro Glu Ala Gln Ile His Glu Gly Phe
 85 90 95
 Gln Glu Leu Leu Arg Thr Leu Asn Gln Pro Asp Ser Gln Leu Gln Leu
 100 105 110
 50 Thr Thr Gly Asn Gly Leu Phe Leu Ser Glu Gly Leu Lys Leu Val Asp
 115 120 125
 Lys Phe Leu Glu Asp Val Lys Lys Leu Tyr His Ser Glu Ala Phe Thr
 130 135 140
 55 Val Asn Phe Gly Asp Thr Glu Glu Ala Lys Lys Gln Ile Asn Asp Tyr
 145 150 155 160
 Val Glu Lys Gly Thr Gln Gly Lys Ile Val Asp Leu Val Lys Glu Leu
 165 170 175
 Asp Arg Asp Thr Val Phe Ala Leu Val Asn Tyr Ile Phe Phe Lys Gly
 180 185 190
 60 Lys Trp Glu Arg Pro Phe Glu Val Lys Asp Thr Glu Glu Asp Phe
 195 200 205
 His Val Asp Gln Val Thr Thr Val Lys Val Pro Met Met Lys Arg Leu
 210 215 220
 65 Gly Met Phe Asn Ile Gln His Cys Lys Lys Leu Ser Ser Trp Val Leu
 225 230 235 240
 Leu Met Lys Tyr Leu Gly Asn Ala Thr Ala Ile Phe Phe Leu Pro Asp
 245 250 255

29

| | 1 | | | 5 | | | 10 | | | 15 | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Met | Asn | Pro | Met | Cys | Ile | Tyr | Arg | Ser | Pro | Glu | Lys | Lys | Ala | Thr | Glu |
| | | | | 20 | | | | | 25 | | | | | 30 | | |
| 5 | Asp | Glu | Gly | Ser | Glu | Gln | Lys | Ile | Pro | Glu | Ala | Thr | Asn | Arg | Arg | Val |
| | | | 35 | | | | | 40 | | | | | 45 | | | |
| | Trp | Glu | Leu | Ser | Lys | Ala | Asn | Ser | Arg | Phe | Ala | Thr | Thr | Phe | Tyr | Gln |
| | | 50 | | | | | 55 | | | | | 60 | | | | |
| 10 | His | Leu | Ala | Asp | Ser | Lys | Asn | Asp | Asn | Asp | Asn | Ile | Phe | Leu | Ser | Pro |
| | 65 | | | | | 70 | | | | | 75 | | | | 80 | |
| | Leu | Ser | Ile | Ser | Thr | Ala | Phe | Ala | Met | Thr | Lys | Leu | Gly | Ala | Cys | Asn |
| | | | | | 85 | | | | | 90 | | | | | 95 | |
| | Asp | Thr | Leu | Gln | Gln | Leu | Met | Glu | Val | Phe | Lys | Phe | Asp | Thr | Ile | Ser |
| | | | 100 | | | | | | 105 | | | | | 110 | | |
| 15 | Glu | Lys | Thr | Ser | Asp | Gln | Ile | His | Phe | Phe | Phe | Ala | Lys | Leu | Asn | Cys |
| | | | 115 | | | | | 120 | | | | | 125 | | | |
| | Arg | Leu | Tyr | Arg | Lys | Ala | Asn | Lys | Ser | Ser | Lys | Leu | Val | Ser | Ala | Asn |
| | | 130 | | | | | 135 | | | | | 140 | | | | |
| 20 | Arg | Leu | Phe | Gly | Asp | Lys | Ser | Leu | Thr | Phe | Asn | Glu | Thr | Tyr | Gln | Asp |
| | 145 | | | | | 150 | | | | | 155 | | | | 160 | |
| | Ile | Ser | Glu | Leu | Val | Tyr | Gly | Ala | Lys | Leu | Gln | Pro | Leu | Asp | Phe | Lys |
| | | | | | 165 | | | | | 170 | | | | | 175 | |
| | Glu | Asn | Ala | Glu | Gln | Ser | Arg | Ala | Ala | Ile | Asn | Lys | Trp | Val | Ser | Asn |
| | | | 180 | | | | | | 185 | | | | | 190 | | |
| 25 | Lys | Thr | Glu | Gly | Arg | Ile | Thr | Asp | Val | Ile | Pro | Ser | Glu | Ala | Ile | Asn |
| | | | 195 | | | | | 200 | | | | | 205 | | | |
| | Glu | Leu | Thr | Val | Leu | Val | Leu | Val | Asn | Thr | Ile | Tyr | Phe | Lys | Gly | Leu |
| | | 210 | | | | | 215 | | | | | 220 | | | | |
| 30 | Trp | Lys | Ser | Lys | Phe | Ser | Pro | Glu | Asn | Thr | Arg | Lys | Glu | Leu | Phe | Tyr |
| | 225 | | | | | 230 | | | | | 235 | | | | 240 | |
| | Lys | Ala | Asp | Gly | Glu | Ser | Cys | Ser | Ala | Ser | Met | Met | Tyr | Gln | Glu | Gly |
| | | | | 245 | | | | | | 250 | | | | 255 | | |
| | Lys | Phe | Arg | Tyr | Arg | Arg | Val | Ala | Glu | Gly | Thr | Gln | Val | Leu | Glu | Leu |
| | | | 260 | | | | | | 265 | | | | | 270 | | |
| 35 | Pro | Phe | Lys | Gly | Asp | Asp | Ile | Thr | Met | Val | Leu | Ile | Leu | Pro | Lys | Pro |
| | | | 275 | | | | | 280 | | | | | 285 | | | |
| | Glu | Lys | Ser | Leu | Ala | Lys | Val | Glu | Lys | Glu | Leu | Thr | Pro | Glu | Val | Leu |
| | | 290 | | | | | 295 | | | | | 300 | | | | |
| 40 | Gln | Glu | Trp | Leu | Asp | Glu | Leu | Glu | Glu | Met | Met | Leu | Val | Val | His | Met |
| | 305 | | | | | 310 | | | | | 315 | | | | 320 | |
| | Pro | Arg | Phe | Arg | Ile | Glu | Asp | Gly | Phe | Ser | Leu | Lys | Glu | Gln | Leu | Gln |
| | | | | 325 | | | | | | 330 | | | | 335 | | |
| | Asp | Met | Gly | Leu | Val | Asp | Leu | Phe | Ser | Pro | Glu | Lys | Ser | Lys | Leu | Pro |
| | | | | 340 | | | | | 345 | | | | | 350 | | |
| 45 | Gly | Ile | Val | Ala | Glu | Gly | Arg | Asp | Asp | Leu | Tyr | Val | Ser | Asp | Ala | Phe |
| | | | 355 | | | | | 360 | | | | | 365 | | | |
| | His | Lys | Ala | Phe | Leu | Glu | Val | Asn | Glu | Glu | Gly | Ser | Glu | Ala | Ala | Ala |
| | | 370 | | | | | 375 | | | | | 380 | | | | |
| 50 | Ser | Thr | Ala | Val | Val | Ile | Ala | Gly | Arg | Ser | Leu | Asn | Pro | Asn | Arg | Val |
| | 385 | | | | | 390 | | | | | 395 | | | | 400 | |
| | Thr | Phe | Lys | Ala | Asn | Arg | Pro | Phe | Leu | Val | Phe | Ile | Arg | Glu | Val | Pro |
| | | | | 405 | | | | | | 410 | | | | 415 | | |
| | Leu | Asn | Thr | Ile | Ile | Phe | Met | Gly | Arg | Val | Ala | Asn | Pro | Cys | Val | Lys |
| | | | | 420 | | | | | 425 | | | | | 430 | | |

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1299 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (B) CLONE: native ATIII DNA sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CACGGAAGCC CTGTGGACAT CTGCACAGCC AAGCCGCGGG ACATTCCCAT GAATCCCATG 60
 TGCATTTACC GCTCCCCGGA GAAGAAGGCA ACTGAGGATG AGGGCTCAGA ACAGAAGATC 120
 CCGGAGGCCA CCAACCGGCG TGTCTGGGAA CTGTCCAAGG CCAATTCCCG CTTTGCTACC 180
 ACTTTCTATC AGCACCTGGC AGATTCCAAG AATGACAATG ATAACATTTT CTTGTACCCC 240
 5 CTGAGTATCT CCACGGCTTT TGCTATGACC AAGCTGGGTG CTTGTAATGA CACCCTCCAG 300
 CAACTGATGG AGGTATTTAA GTTTGACACC ATATCTGAGA AAACATCTGA TCAGATCCAC 360
 TTCTTCTTTG CCAAACGTAA CTGCCGACTC TATCGAAAAG CCAACAAATC CTCCAAGTTA 420
 GTATCAGCCA ATCGCCTTTT TGGAGACAAA TCCCTTACCT TCAATGAGAC CTACCAGGAC 480
 ATCAGTGAGT TGGTATATGG AGCCAAGCTC CAGCCCCTGG ACTTCAAGGA AAATGCAGAG 540
 10 CAATCCAGAG CGGCCATCAA CAAATGGGTG TCCAATAAGA CCGAAGGCCG AATCACCAGT 600
 GTCATTCCCT CGGAAGCCAT CAATGAGCTC ACTGTTCTGG TGCTGGTTAA CACCATTTAC 660
 TTCAAGGGCC TGTGGAAGTC AAAGTTCAGC CCTGAGAACA CAAGGAAGGA ACTGTTCTAC 720
 AAGGCTGATG GAGAGTCGTG TTCAGCATCT ATGATGTACC AGGAAGGCCA GTTCCGTTAT 780
 CGGCGCGTGG CTGAAGGCAC CCAGGTGCTT GAGTTGCCCT TCAAAGGTGA TGACATCACC 840
 15 ATGGTCCTCA TCTTGCCCAA GCCTGAGAAG AGCCTGGCCA AGGTGGAGAA GGAAGTCACC 900
 CCAGAGGTGC TGCAGGAGTG GCTGGATGAA TGGAGGAGA TGATGCTGGT GGTTCACATG 960
 CCCCCTTCC GCATTGAGGA CGGCTTCAGT TTGAAGGAGC AGCTGCAAGA CATGGCCTT 1020
 GTCGATCTGT TCAGCCCTGA AAAGTCCAAA CTCCAGGTA TTGTTGCAGA AGGCCGAGAT 1080
 GACCTCTATG TCTCAGATGC ATTCCATAAG GCATTTCTTG AGGTAAATGA AGAAGGCAGT 1140
 20 CAAGCAGCTG CAAGTACCGC TGTTGTGATT GCTGGCCGTT CGCTAAACCC CAACAGGGTG 1200
 ACTTTCAAGG CCAACAGGCC CTTCTGGTT TTTATAAGAG AAGTTCCTCT GAACACTATT 1260
 ATCTTCATGG GCAGAGTAGC CAACCCTTGT GTTAAGTAA 1299

(2) INFORMATION FOR SEQ ID NO:11:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 585 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: mature HSA amino acid sequence

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1 5 10 15
 40 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20 25 30
 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35 40 45
 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50 55 60
 45 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65 70 75 80
 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
 85 90 95
 50 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
 100 105 110
 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
 115 120 125
 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
 130 135 140
 55 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
 145 150 155 160
 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
 165 170 175
 60 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
 180 185 190
 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
 195 200 205
 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
 210 215 220
 65 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
 225 230 235 240
 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | | | | | 245 | | | | | 250 | | | | | 255 | |
| | Arg | Ala | Asp | Leu | Ala | Lys | Tyr | Ile | Cys | Glu | Asn | Gln | Asp | Ser | Ile | Ser |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| 5 | Ser | Lys | Leu | Lys | Glu | Cys | Cys | Glu | Lys | Pro | Leu | Leu | Glu | Lys | Ser | His |
| | | | 275 | | | | | 280 | | | | | 285 | | | |
| | Cys | Ile | Ala | Glu | Val | Glu | Asn | Asp | Glu | Met | Pro | Ala | Asp | Leu | Pro | Ser |
| | | 290 | | | | | 295 | | | | | 300 | | | | |
| | Leu | Ala | Ala | Asp | Phe | Val | Glu | Ser | Lys | Asp | Val | Cys | Lys | Asn | Tyr | Ala |
| | 305 | | | | | 310 | | | | | 315 | | | | 320 | |
| 10 | Glu | Ala | Lys | Asp | Val | Phe | Leu | Gly | Met | Phe | Leu | Tyr | Glu | Tyr | Ala | Arg |
| | | | | 325 | | | | | | 330 | | | | | 335 | |
| | Arg | His | Pro | Asp | Tyr | Ser | Val | Val | Leu | Leu | Leu | Arg | Leu | Ala | Lys | Thr |
| | | | 340 | | | | | | 345 | | | | | 350 | | |
| | Tyr | Glu | Thr | Thr | Leu | Glu | Lys | Cys | Cys | Ala | Ala | Ala | Asp | Pro | His | Glu |
| 15 | | | 355 | | | | | 360 | | | | | 365 | | | |
| | Cys | Tyr | Ala | Lys | Val | Phe | Asp | Glu | Phe | Lys | Pro | Leu | Val | Glu | Glu | Pro |
| | | 370 | | | | | 375 | | | | | 380 | | | | |
| | Gln | Asn | Leu | Ile | Lys | Gln | Asn | Cys | Glu | Leu | Phe | Lys | Gln | Leu | Gly | Glu |
| | 385 | | | | 390 | | | | | | 395 | | | | 400 | |
| 20 | Tyr | Lys | Phe | Gln | Asn | Ala | Leu | Leu | Val | Arg | Tyr | Thr | Lys | Lys | Val | Pro |
| | | | | 405 | | | | | 410 | | | | | 415 | | |
| | Gln | Val | Ser | Thr | Pro | Thr | Leu | Val | Glu | Val | Ser | Arg | Asn | Leu | Gly | Lys |
| | | | 420 | | | | | | 425 | | | | 430 | | | |
| | Val | Gly | Ser | Lys | Cys | Cys | Lys | His | Pro | Glu | Ala | Lys | Arg | Met | Pro | Cys |
| 25 | | | 435 | | | | | 440 | | | | | 445 | | | |
| | Ala | Glu | Asp | Tyr | Leu | Ser | Val | Val | Leu | Asn | Gln | Leu | Cys | Val | Leu | His |
| | | 450 | | | | | 455 | | | | | 460 | | | | |
| | Glu | Lys | Thr | Pro | Val | Ser | Asp | Arg | Val | Thr | Lys | Cys | Cys | Thr | Glu | Ser |
| | 465 | | | | | 470 | | | | | 475 | | | | 480 | |
| 30 | Leu | Val | Asn | Arg | Arg | Pro | Cys | Phe | Ser | Ala | Leu | Glu | Val | Asp | Glu | Thr |
| | | | | 485 | | | | | 490 | | | | | 495 | | |
| | Tyr | Val | Pro | Lys | Glu | Phe | Asn | Ala | Glu | Thr | Phe | Thr | Phe | His | Ala | Asp |
| | | | 500 | | | | | | 505 | | | | | 510 | | |
| | Ile | Cys | Thr | Leu | Ser | Glu | Lys | Glu | Arg | Gln | Ile | Lys | Lys | Gln | Thr | Ala |
| 35 | | | 515 | | | | | 520 | | | | | 525 | | | |
| | Leu | Val | Glu | Leu | Val | Lys | His | Lys | Pro | Lys | Ala | Thr | Lys | Glu | Gln | Leu |
| | | 530 | | | | | 535 | | | | | 540 | | | | |
| | Lys | Ala | Val | Met | Asp | Asp | Phe | Ala | Ala | Phe | Val | Glu | Lys | Cys | Cys | Lys |
| | 545 | | | | 550 | | | | | 555 | | | | | 560 | |
| 40 | Ala | Asp | Asp | Lys | Glu | Thr | Cys | Phe | Ala | Glu | Gly | Lys | Lys | Leu | Val | |
| | | | | 565 | | | | | | 570 | | | | 575 | | |
| | Ala | Ala | Ser | Gln | Ala | Ala | Leu | Gly | Leu | | | | | | | |
| | | | | 580 | | | | 585 | | | | | | | | |

45 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1865 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: native coding sequence of mature HSA

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

| | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|-----|
| | AGATGCACAC | AAGAGTGAGG | TTGCTCATCG | GTTTAAAGAT | TTGGGAGAAG | AAAATTTCAA | 60 |
| | AGCCTTGGTG | TTGATTGCCT | TTGCTCAGTA | TCTTCAGCAG | TGTCCATTTG | AAGATCATGT | 120 |
| 60 | AAAATTAGTG | AATGAAGTAA | CTGAATTGTC | AAAAACATGT | GTAGCTGATG | AGTCAGCTGA | 180 |
| | AAATTGTGAC | AAATCACTTC | ATACCCTTTT | TGGAGACAAA | TTATGCACAG | TTGCAACTCT | 240 |
| | TCGTGAAACC | TATGGTGAAA | TGGCTGACTG | CTGTGCAAAA | CAAGAACCTG | AGAGAAATGA | 300 |
| | ATGCTTCTTG | CAACACAAAG | ATGACAACCC | AAACCTCCCC | CGATTGGTGA | GACCAGAGGT | 360 |
| | TGATGTGATG | TGCACTGCTT | TTCATGACAA | TGAAGAGACA | TTTTTGAAAA | AATACTTATA | 420 |
| 65 | TGAAATTGCC | AGAAGACATC | CTTACTTTTA | TGCCCCGGAA | CTCCTTTTCT | TTGCTAAAAG | 480 |
| | GTATAAAGCT | GCTTTTACAG | AATGTTGCCA | AGCTGCTGAT | AAAGCTGCCT | GCCTGTTGCC | 540 |
| | AAAGCTCGAT | GAACTTCGGG | ATGAAGGGAA | GGCTTCGTCT | GCCAAACAGA | GACTCAAATG | 600 |

```

TGCCAGTCTC CAAAAATTTG GAGAAAGAGC TTTCAAAGCA TGGGCAGTGG CTCGCCTGAG 660
CCAGAGATTT CCCAAAGCTG AGTTTGCAGA AGTTTCCAAG TTAGTGACAG ATCTTACCAA 720
AGTCCACACG GAATGCTGCC ATGGAGATCT GCTTGAATGT GCTGATGACA GGGCGGACCT 780
TGCCAAGTAT ATCTGTGAAA ATCAGGATTC GATCTCCAGT AAACCTGAAG AATGCTGTGA 840
5 AAAACCTCTG TTGGAAAAAT CCCACTGCAT TGCCGAAGTG GAAAATGATG AGATGCCTGC 900
TGACTTGCCT TCATTAGCTG CTGATTTTGT TGAAAGTAAG GATGTTTGCA AAAACTATGC 960
TGAGGCAAAG GATGTCTTCC TGGGCATGTT TTTGTATGAA TATGCAAGAA GGCATCCTGA 1020
TTACTCTGTC GTGCTGCTGC TGAGACTTGC CAAGACATAT GAAACCACTC TAGAGAAGTG 1080
CTGTGCCGCT GCAGATCCTC ATGAATGCTA TGCCAAAGTG TTCGATGAAT TTAAACCTCT 1140
10 TGTGGAAGAG CCTCAGAATT TAATCAAACA AAACCTGTGAG CTTTTTAAGC AGCTTGGAGA 1200
GTACAAATTC CAGAATGCGC TATTAGTTCC TTACACCAAG AAAGTACCCC AAGTGTCAAC 1260
TCCAACCTCT GTAGAGGTCT CAAGAAACCT AGGAAAAGTG GGCAGCAAAT GTTGTAACA 1320
TCCTGAAGCA AAAAGAATGC CCTGTGCAGA AGACTATCTA TCCGTGGTCC TGAACCACTT 1380
ATGTGTGTTG CATGAGAAAA CGCCAGTAAG TGACAGAGTC ACAAATGCT GCACAGAGTC 1440
15 CTTGGTGAAC AGGCGACCAT GCTTTTCAGC TCTGGAAGTC GATGAAACAT ACGTTCCCAA 1500
AGAGTTTAAT GCTGAAACAT TCACCTTCCA TGCACATATA TGCACATTT CTGAGAAGGA 1560
GAGACAAATC AAGAAACAAA CTGCACTTGT TGAGCTTGTG AAACACAAGC CCAAGGCAAC 1620
AAAAGAGCAA CTGAAAGCTG TTATGGATGA TTTTCGCAGCT TTTGTAGAGA AGTGCTGCAA 1680
GGCTGACGAT AAGGAGACCT GCTTTGCCGA GGAGGGTAAA AAACCTTGTG CTGCAAGTCA 1740
20 AGCTGCCTTA GGCTTATAAC ATCTACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG 1800
AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT TTTTTCGTTG GTGTAAAGCC 1860
AACAC

```

(2) INFORMATION FOR SEQ ID NO:13:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: native proBPN' amino acid sequence

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

Ala Gly Lys Ser Asn Gly Glu Lys Lys Tyr Ile Val Gly Phe Lys Gln
1 5 10 15
Thr Met Ser Thr Met Ser Ala Ala Lys Lys Asp Val Ile Ser Glu
20 25 30
40 Lys Gly Gly Lys Val Gln Lys Gln Phe Lys Tyr Val Asp Ala Ala Ser
35 40 45
Ala Thr Leu Asn Glu Lys Ala Val Lys Glu Leu Lys Lys Asp Pro Ser
50 55 60
45 Val Ala Tyr Val Glu Glu Asp His Val Ala His Ala Tyr Ala Gln Ser
65 70 75 80
Val Pro Tyr Gly Val Ser Gln Ile Lys Ala Pro Ala Leu His Ser Gln
85 90 95
50 Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp Ser Gly Ile
100 105 110
Asp Ser Ser His Pro Asp Leu Lys Val Ala Gly Gly Ala Ser Met Val
115 120 125
Pro Ser Glu Thr Asn Pro Phe Gln Asp Asn Asn Ser His Gly Thr His
130 135 140
55 Val Ala Gly Thr Val Ala Ala Leu Asn Asn Ser Ile Gly Val Leu Gly
145 150 155 160
Val Ala Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu Gly Ala Asp
165 170 175
60 Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu Trp Ala Ile
180 185 190
Ala Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly Pro Ser Gly
195 200 205
Ser Ala Ala Leu Lys Ala Ala Val Asp Lys Ala Val Ala Ser Gly Val
210 215 220
65 Val Val Val Ala Ala Ala Gly Asn Glu Gly Thr Ser Gly Ser Ser Ser
225 230 235 240
Thr Val Gly Tyr Pro Gly Lys Tyr Pro Ser Val Ile Ala Val Gly Ala

```

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | | | | 245 | | | | | | 250 | | | | | 255 | |
| | Val | Asp | Ser | Ser | Asn | Gln | Arg | Ala | Ser | Phe | Ser | Ser | Val | Gly | Pro | Glu |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| | Leu | Asp | Val | Met | Ala | Pro | Gly | Val | Ser | Ile | Gln | Ser | Thr | Leu | Pro | Gly |
| 5 | | | 275 | | | | | 280 | | | | | 285 | | | |
| | Asn | Lys | Tyr | Gly | Ala | Tyr | Asn | Gly | Thr | Ser | Met | Ala | Ser | Pro | His | Val |
| | | 290 | | | | | 295 | | | | | 300 | | | | |
| | Ala | Gly | Ala | Ala | Ala | Leu | Ile | Leu | Ser | Lys | His | Pro | Asn | Trp | Thr | Asn |
| | | 305 | | | | 310 | | | | | 315 | | | | | 320 |
| 10 | Thr | Gln | Val | Arg | Ser | Ser | Leu | Glu | Asn | Thr | Thr | Thr | Lys | Leu | Gly | Asp |
| | | | | 325 | | | | | | 330 | | | | | 335 | |
| | Ser | Phe | Tyr | Tyr | Gly | Lys | Gly | Leu | Ile | Asn | Val | Gln | Ala | Ala | Ala | Gln |
| | | | 340 | | | | | 345 | | | | | | 350 | | |

15 (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1056 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (B) CLONE: native proBPN' coding sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

| | | | | | | | |
|----|------------|------------|------------|------------|------------|-------------|------|
| | GCAGGGAAAT | CAAACGGGGA | AAAGAAATAT | ATTGTCGGGT | TAAACAGAC | AATGAGCAGC | 60 |
| | ATGAGCGCCG | CTAAGAAGAA | AGATGTCATT | TCTGAAAAAG | GCGGGAAAGT | GCAAAAGCAA | 120 |
| 30 | TTCAAATATG | TAGACGCAGC | TTCAGCTACA | TAAACGAAA | AAGCTGTAAA | AGAATTGAAA | 180 |
| | AAAGACCCGA | GCGTCGCTTA | CGTTGAAGAA | GATCACGTAG | CACATGCGTA | CGCGCAGTCC | 240 |
| | GTGCCTTACG | GCGTATCACA | AATTAAAGCC | CCTGCTCTGC | ACTCTCAAGG | CTACACTGGA | 300 |
| | TCAAATGTTA | AAGTAGCGGT | TATCGACAGC | GGTATCGATT | CTTCTCATCC | TGATTTAAAG | 360 |
| | GTAGCAGGCG | GAGCCAGCAT | GGTTCCTTCT | GAAACAAATC | CTTTCCAAGA | CAACAACCTCT | 420 |
| 35 | CACGGAACTC | ACGTTGCCGG | CACAGTTGCG | GCTCTTAATA | ACTCAATCGG | TGTATTAGGC | 480 |
| | GTTGCGCCAA | GCGCATCACT | TTACGCTGTA | AAAGTTCTCG | GTGCTGACGG | TTCCGGCCAA | 540 |
| | TACAGCTGGA | TCATTAACGG | AATCGAGTGG | GCGATCGCAA | ACAATATGGA | CGTTATTAAAC | 600 |
| | ATGAGCCTCG | GCGGACCTTC | TGGTTCTGCT | GCTTTAAAAG | CGGCAGTTGA | TAAAGCCGTT | 660 |
| | GCATCCGGCG | TCGTAGTCGT | TGCGGCAGCC | GGTAACGAAG | GCACTTCCGG | CAGCTCAAGC | 720 |
| 40 | ACAGTGGGCT | ACCCTGGTAA | ATACCCTTCT | GTCATTGCAG | TAGGCGCTGT | TGACAGCAGC | 780 |
| | AACCAAAGAG | CATCTTTCTC | AAGCGTAGGA | CCTGAGCTTG | ATGTCATGGC | ACCTGGCGTA | 840 |
| | TCTATCCAAA | GCACGTTTCC | TGGAAACAAA | TACGGGGCCT | ACAACGGTAC | GTCAATGGCA | 900 |
| | TCTCCGCACG | TTGCCGGAGC | GGCTGCTTTG | ATTCTTTCTA | AGCACCCGAA | CTGGACAAAC | 960 |
| | ACTCAAGTCC | GCAGCAGTTT | AGAAAACACC | ACTACAAAAC | TTGGTGATTG | TTTCTACTAT | 1020 |
| 45 | GGAAAAGGGC | TGATCAACGT | ACAGGCGGCA | GCTCAG | | | 1056 |

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (B) CLONE: subtilisin BPN' pro-peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 60 | Ala | Gly | Lys | Ser | Asn | Gly | Glu | Lys | Lys | Tyr | Ile | Val | Gly | Phe | Lys | Gln |
| | 1 | | | | 5 | | | | 10 | | | | | 15 | | |
| | Thr | Met | Ser | Thr | Met | Ser | Ala | Ala | Lys | Lys | Lys | Asp | Val | Ile | Ser | Glu |
| | | | | 20 | | | | 25 | | | | | 30 | | | |
| | Lys | Gly | Gly | Lys | Val | Gln | Lys | Gln | Phe | Lys | Tyr | Val | Asp | Ala | Ala | Ser |
| 65 | | | 35 | | | | 40 | | | | | 45 | | | | |
| | Ala | Thr | Leu | Asn | Glu | Lys | Ala | Val | Lys | Glu | Leu | Lys | Lys | Asp | Pro | Ser |
| | | 50 | | | | 55 | | | | | 60 | | | | | |

Val Ala Tyr Val Glu Glu Asp His Val Ala His Ala Tyr
65 70 75

5 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 275 amino acids

(B) TYPE: amino acid

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: native mature BPN' amino acid sequence

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Ala | Gln | Ser | Val | Pro | Tyr | Gly | Val | Ser | Gln | Ile | Lys | Ala | Pro | Ala | Leu |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| 20 | His | Ser | Gln | Gly | Tyr | Thr | Gly | Ser | Asn | Val | Lys | Val | Ala | Val | Ile | Asp |
| | | | | 20 | | | | | 25 | | | | | 30 | | |
| | Ser | Gly | Ile | Asp | Ser | Ser | His | Pro | Asp | Leu | Lys | Val | Ala | Gly | Gly | Ala |
| | | | 35 | | | | | 40 | | | | | 45 | | | |
| 25 | Ser | Met | Val | Pro | Ser | Glu | Thr | Asn | Pro | Phe | Gln | Asp | Asn | Asn | Ser | His |
| | | 50 | | | | | 55 | | | | | 60 | | | | |
| | Gly | Thr | His | Val | Ala | Gly | Thr | Val | Ala | Ala | Leu | Asn | Asn | Ser | Ile | Gly |
| | 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| | Val | Leu | Gly | Val | Ala | Pro | Ser | Ala | Ser | Leu | Tyr | Ala | Val | Lys | Val | Leu |
| | | | | 85 | | | | | | 90 | | | | | 95 | |
| 30 | Gly | Ala | Asp | Gly | Ser | Gly | Gln | Tyr | Ser | Trp | Ile | Ile | Asn | Gly | Ile | Glu |
| | | | | 100 | | | | | 105 | | | | | 110 | | |
| | Trp | Ala | Ile | Ala | Asn | Asn | Met | Asp | Val | Ile | Asn | Met | Ser | Leu | Gly | Gly |
| | | | 115 | | | | | 120 | | | | | 125 | | | |
| 35 | Pro | Ser | Gly | Ser | Ala | Ala | Leu | Lys | Ala | Ala | Val | Asp | Lys | Ala | Val | Ala |
| | | 130 | | | | | 135 | | | | | 140 | | | | |
| | Ser | Gly | Val | Val | Val | Val | Ala | Ala | Gly | Asn | Glu | Gly | Thr | Ser | Gly | |
| | 145 | | | | | 150 | | | | 155 | | | | | 160 | |
| | Ser | Ser | Ser | Thr | Val | Gly | Tyr | Pro | Gly | Lys | Tyr | Pro | Ser | Val | Ile | Ala |
| | | | | 165 | | | | | | 170 | | | | | 175 | |
| 40 | Val | Gly | Ala | Val | Asp | Ser | Ser | Asn | Gln | Arg | Ala | Ser | Phe | Ser | Ser | Val |
| | | | | 180 | | | | | 185 | | | | | 190 | | |
| | Gly | Pro | Glu | Leu | Asp | Val | Met | Ala | Pro | Gly | Val | Ser | Ile | Gln | Ser | Thr |
| | | | 195 | | | | | 200 | | | | | 205 | | | |
| 45 | Leu | Pro | Gly | Asn | Lys | Tyr | Gly | Ala | Tyr | Asn | Gly | Thr | Ser | Met | Ala | Ser |
| | | 210 | | | | | 215 | | | | | 220 | | | | |
| | Pro | His | Val | Ala | Gly | Ala | Ala | Ala | Leu | Ile | Leu | Ser | Lys | His | Pro | Asn |
| | 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| | Trp | Thr | Asn | Thr | Gln | Val | Arg | Ser | Ser | Leu | Glu | Asn | Thr | Thr | Thr | Lys |
| | | | | 245 | | | | | | 250 | | | | | 255 | |
| 50 | Leu | Gly | Asp | Ser | Phe | Tyr | Tyr | Gly | Lys | Gly | Leu | Ile | Asn | Val | Gln | Ala |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| | Ala | Ala | Gln | | | | | | | | | | | | | |
| | | | 275 | | | | | | | | | | | | | |

55 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 275 amino acids

(B) TYPE: amino acid

60 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: amino acid sequence of mature BPN' variant

65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 5 | Ala | Gln | Ser | Val | Pro | Tyr | Gly | Val | Ser | Gln | Ile | Lys | Ala | Pro | Ala | Leu |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| | His | Ser | Gln | Gly | Tyr | Thr | Gly | Ser | Asn | Val | Lys | Val | Ala | Val | Ile | Asp |
| | | | | 20 | | | | | 25 | | | | | 30 | | |
| | Ser | Gly | Ile | Asp | Ser | Ser | His | Pro | Asp | Leu | Lys | Val | Ala | Gly | Gly | Ala |
| | | | 35 | | | | | 40 | | | | | 45 | | | |
| 10 | Ser | Met | Val | Pro | Ser | Glu | Thr | Asn | Pro | Phe | Gln | Asp | Thr | Asn | Ser | His |
| | | 50 | | | | | 55 | | | | | 60 | | | | |
| | Gly | Thr | His | Val | Ala | Gly | Thr | Val | Ala | Ala | Leu | Thr | Asn | Ser | Ile | Gly |
| | 65 | | | | | 70 | | | | | 75 | | | | 80 | |
| | Val | Leu | Gly | Val | Ala | Pro | Ser | Ala | Ser | Leu | Tyr | Ala | Val | Lys | Val | Leu |
| | | | | | 85 | | | | | 90 | | | | | 95 | |
| 15 | Gly | Ala | Asp | Gly | Ser | Gly | Gln | Tyr | Ser | Trp | Ile | Ile | Asn | Gly | Ile | Glu |
| | | | | 100 | | | | | 105 | | | | | 110 | | |
| | Trp | Ala | Ile | Ala | Asn | Asn | Met | Asp | Val | Ile | Thr | Met | Ser | Leu | Gly | Gly |
| | | | 115 | | | | | 120 | | | | | 125 | | | |
| 20 | Pro | Ser | Gly | Ser | Ala | Ala | Leu | Lys | Ala | Ala | Val | Asp | Lys | Ala | Val | Ala |
| | | | 130 | | | | 135 | | | | | 140 | | | | |
| | Ser | Gly | Val | Val | Val | Val | Ala | Ala | Ala | Gly | Asn | Glu | Gly | Thr | Ser | Gly |
| | | | | | | 150 | | | | | 155 | | | | | 160 |
| | Ser | Ser | Ser | Thr | Val | Gly | Tyr | Pro | Gly | Lys | Tyr | Pro | Ser | Val | Ile | Ala |
| | | | | | 165 | | | | | 170 | | | | | 175 | |
| 25 | Val | Gly | Ala | Val | Asp | Ser | Ser | Asn | Gln | Arg | Ala | Ser | Phe | Ser | Ser | Val |
| | | | | | 180 | | | | 185 | | | | | 190 | | |
| | Gly | Pro | Glu | Leu | Asp | Val | Met | Ala | Pro | Gly | Val | Ser | Ile | Gln | Ser | Thr |
| | | | 195 | | | | | 200 | | | | | 205 | | | |
| 30 | Leu | Pro | Gly | Asn | Lys | Tyr | Gly | Ala | Tyr | Ser | Gly | Thr | Ser | Met | Ala | Ser |
| | | | 210 | | | | 215 | | | | | | 220 | | | |
| | Pro | His | Val | Ala | Gly | Ala | Ala | Ala | Leu | Ile | Leu | Ser | Lys | His | Pro | Thr |
| | | | | | | 230 | | | | | 235 | | | | | 240 |
| | Trp | Thr | Asn | Thr | Gln | Val | Arg | Ser | Ser | Leu | Glu | Asn | Thr | Thr | Thr | Lys |
| | | | | | 245 | | | | | 250 | | | | | 255 | |
| 35 | Leu | Gly | Asp | Ser | Phe | Tyr | Tyr | Gly | Lys | Gly | Leu | Ile | Asn | Val | Gln | Ala |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| | Ala | Ala | Gln | | | | | | | | | | | | | |
| | | | | 275 | | | | | | | | | | | | |

40

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1260 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45

(vii) IMMEDIATE SOURCE:

- (B) CLONE: codon-optimized 3D signal peptide-AAT DNA sequence

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

| | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|-----|
| 55 | ATGAAGAACA | CCTCCTCCCT | CTGCCCTCTG | CTGCTCGTGG | TCCTCTGCTC | CCTGACCTGC | 60 |
| | AACAGCGGCC | AGGCCGAGGA | CCCGCAGGGC | GACGCCGCCC | AGAAGACCGA | CACCAGCCAC | 120 |
| | CACGACCAGG | ACCACCCGAC | GTTCAACAAG | ATCACCCCGA | ATTGGCCGA | ATTCGCCTTC | 180 |
| | AGCCTGTACC | GCCAGCTCGC | GCACCACTCC | AACTCCACCA | ACATCTTCTT | CAGCCCGGTG | 240 |
| | AGCATCGCCA | CCGCCTTCGC | CATGCTGTCC | CTGGGTACCA | AGGCGGACAC | CCACGACGAG | 300 |
| | ATCCTCGAAG | GGCTGAACTT | CAACCTGACG | GAGATCCCAG | AGGCGCAGAT | CCACGAGGGC | 360 |
| 60 | TTCCAGGAGC | TGCTCAGGAC | GCTCAACCAG | CCGGAATCCC | AGCTCCAGCT | CACCACCGGC | 420 |
| | AACGGGCTCT | TCCTGTCCGA | GGGCCTCAAG | CTCGTCGATA | AGTTCTTGGA | GGACGTGAAG | 480 |
| | AAGCTCTACC | ACTCCGAGGC | GTTCAACGTC | AACTTCGGGG | ACACCGAGGA | GGCCAAGAAG | 540 |
| | CAGATCAACG | ACTACGTGCA | GAAGGGGACC | CAGGGCAAGA | TCGTGGACCT | GGTCAAGGAA | 600 |
| | TTGGACAGGG | ACACCGTCTT | CGCGCTCGTC | AACTACATCT | TCTTCAAGGG | CAAGTGGGAG | 660 |
| 65 | CGCCCGTTTC | AGGTGAAGGA | CACCGAGGAG | GAGGACTTCC | ACGTCGACCA | GGTCACCACC | 720 |
| | GTCAAGGTCC | CGATGATGAA | GAGGCTCGGC | ATGTTCAACA | TCCAGCACTG | CAAGAAGCTC | 780 |
| | TCCAGCTGGG | TGCTCCTCAT | GAAGTACCTG | GGGAACGCCA | CCGCCATCTT | CTTCTGCGCG | 840 |

GACGAGGGCA AGCTCCAGCA CCTGGAGAAC GAGCTGACGC ACGACATCAT CACGAAGTTC 900
 CTGGAGAACG AGGACAGGCG CTCCGCTAGC CTCCACCTCC CGAAGCTGAG CATCACCGGC 960
 ACGTACGACC TGAAGAGCGT GCTGGGCCAG CTGGGCATCA CGAAGGTCTT CAGCAACGGC 1020
 GCGGACCTCT CCGGCGTGAC GGAGGAGGCC CCCCTGAAGC TCTCCAAGGC CGTGCAACAAG 1080
 5 GCGGTGCTCA CGATCGACGA GAAGGGGACG GAAGCTGCCG GGGCCATGTT CCTGGAGGCC 1140
 ATCCCCATGT CCATCCCGCC CGAGGTCAAG TTCAACAAGC CTTTCGTCTT CCTGATGATC 1200
 GAGCAGAACA CGAAGAGCCC CCTCTTCATG GGGAAAGTCG TCAACCCAC GCAGAAGTGA 1260

(2) INFORMATION FOR SEQ ID NO:19:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1382 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: codon-optimized 3D signal peptide-ATIII DNA sequen.

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGAAGAACA CCTCCTCCCT CTGCCTCCTG CTGCTCGTGG TCCTCTGCTC CTGACCTGC 60
 AACAGCGGCC AGGCCACGG AAGCCCTGTG GACATCTGCA CAGCCAAGCC GCGGGACATT 120
 CCCATGAATC CCATGTGCAT TTACCGCTCC CCGGAGAAGA AGGCAACTGA GGATGAGGGC 180
 25 TCAGAACAGA AGATCCCGGA GGCCACCAAC CGGCGTGTCT GGGAACTGTC CAAGGCCAAT 240
 TCCCGCTTTG CTACCACTTT CTATCAGCAC CTGGCAGATT CCAAGAATGA CAATGATAAC 300
 ATTTTCCTGT CACCCCTGAG TATCTCCACG GCTTTTGCTA TGACCAAGCT GGGTGCCTGT 360
 AATGACACCC TCCAGCAACT GATGGAGGTA TTTAAGTTTG ACACCATATC TGAGAAAACA 420
 TCTGATCAGA TCCACTTCTT CTTTGCCAAA CTGAAGTGC GACTCTATCG AAAAGCCAAC 480
 30 AAATCCTCCA AGTTAGTATC AGCCAATCGC CTTTTTGGAG ACAATCCCT TACCTTCAAT 540
 GAGACCTACC AGGACATCAG TGAGTTGGTA TATGGAGCCA AGCTCCAGCC CCTGGACTTC 600
 AAGGAAAATG CAGAGCAATC CAGAGCGGCC ATCAACAAAT GGGTGTCCAA TAAGACCGAA 660
 GGCCGAATCA CCGATGTCAT TCCCTCGGAA GCCATCAATG AGCTCACTGT TCTGGTGTCTG 720
 GTTAACACCA TTTACTTCAA GGGCCTGTGG AAGTCAAAGT TCAGCCCTGA GAACACAAGG 780
 35 AAGGAAGTGT TCTACAAGGC TGATGGAGAG TCGTGTTCAG CATCTATGAT GTACCAGGAA 840
 GGCAAGTTCC GTTATCGGCG CGTGGCTGAA GGCACCCAGG TGCTTGAGTT GCCCTTCAAA 900
 GGTGATGACA TCACCATGGT CCTCATCTTG CCCAAGCCTG AGAAGAGCCT GGCCAAGGTG 960
 GAGAAGGAAC TCACCCAGA GGTGCTGCAG GAGTGGCTGG ATGAATTGGA GGAGATGATG 1020
 CTGGTGGTTC ACATGCCCCG CTTCGCATT GAGGACGGCT TCAGTTTGAA GGAGCAGCTG 1080
 40 CAAGACATGG GCCTTGTCGA TCTGTTTCAG CCTGAAAAGT CCAAATCCC AGGTATTGTT 1140
 GCAGAAGGCC GAGATGACCT CTATGTCTCA GATGCATTCC ATAAGGCATT TCTTGAGGTA 1200
 AATGAAGAAG GCAGTGAAGC AGCTGCAAGT ACCGCTGTTG TGATTGCTGG CCGTTCGCTA 1260
 AACCCCAACA GGGTGACTTT CAAGGCCAAC AGGCCCTTCC TGGTTTTTAT AAGAGAAGTT 1320
 CCTCTGAACA CTATTATCTT CATGGGCAGA GTAGCCAACC CTTGTGTTAA GTAACCTCGAG 1380
 45 CC 1382

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1940 base pairs.

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

55

(vii) IMMEDIATE SOURCE:

(B) CLONE: codon-optimized 3D signal peptide-HSA DNA sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATGAAGAACA CCTCCTCCCT CTGCCTCCTG CTGCTCGTGG TCCTCTGCTC CTGACCTGC 60
 AACAGCGGCC AGGCCAGATG CACACAAGAG TGAGGTTGCT CATCGGTTTA AAGATTTGGG 120
 AGAAGAAAAT TTCAAAGCCT TGGTGTGTGAT TGCCTTTGCT CAGTATCTTC AGCAGTGTCC 180
 ATTTGAAGAT CATGTAAAT TAGTGAATGA AGTAACTGAA TTTGCAAAAA CATGTGTAGC 240
 TGATGAGTCA GCTGAAAATT GTGACAAATC ACTTCATACC CTTTTGGAG ACAAAATTATG 300
 65 CACAGTTGCA ACTCTTCGTG AAACCTATGG TGAAATGGCT GACTGCTGTG CAAAACAAGA 360
 ACCTGAGAGA AATGAATGCT TCTTGCAACA CAAAGATGAC AACCCAAACC TCCCCCGATT 420
 GGTGAGACCA GAGGTTGATG TGATGTGCAC TGCTTTTCAT GACAATGAAG AGACATTTT 480

GAAAAAATAC TTATATGAAA TTGCCAGAAG ACATCCTTAC TTTTATGCCC CGGAACTCCT 540
 TTTCTTTGCT AAAAGGTATA AAGCTGCTTT TACAGAATGT TGCCAAGCTG CTGATAAAGC 600
 TGCCTGCCCTG TTGCCAAAGC TCGATGAACT TCGGGATGAA GGGAAAGGCTT CGTCTGCCAA 660
 ACAGAGACTC AAATGTGCCA GTCTCCAAAA ATTTGGAGAA AGAGCTTTCA AAGCATGGGC 720
 5 AGTGGCTCGC CTGAGCCAGA GATTTCCTCA AGCTGAGTTT GCAGAAGTTT CCAAGTTAGT 780
 GACAGATCTT ACCAAAGTCC ACACGGAATG CTGCCATGGA GATCTGCTTG AATGTGCTGA 840
 TGACAGGGCG GACCTTGCCA AGTATATCTG TGAAAATCAG GATTCGATCT CCAGTAAACT 900
 GAAGGAATGC TGTGAAAAAC CTCTGTTGGA AAAATCCAC TGCAATTGCCG AAGTGGAAAA 960
 TGATGAGATG CCTGCTGACT TGCTTCATT AGCTGCTGAT TTTGTTGAAA GTAAGGATGT 1020
 10 TTGCAAAAAAC TATGCTGAGG CAAAGATGT CTTCTGGGC ATGTTTTTGT ATGAATATGC 1080
 AAGAAGGCAT CCTGATTACT CTGCTGTGCT GCTGCTGAGA CTTGCCAAGA CATATGAAAC 1140
 CACTCTAGAG AAGTGCTGTG CCGCTGCAGA TCCTCATGAA TGCTATGCCA AAGTGTTCTGA 1200
 TGAATTTAAA CCTCTTGTTG AAGAGCCTCA GAATTTAATC AAACAAAAC GTGAGCTTTT 1260
 TAAGCAGCTT GGAGAGTACA AATTCCAGAA TGCGTTATTA GTTCGTTACA CCAAGAAAGT 1320
 15 ACCCCAAGTG TCAACTCCAA CTCTGTAGA GGTCTCAAGA AACCTAGGAA AAGTGGGCAG 1380
 CAAATGTTGT AAACATCCTG AAGCAAAAAG AATGCCCTGT GCAGAAGACT ATCTATCCGT 1440
 GGTCTGAAC CAGTTATGTG TGTGTCATGA GAAAACGCCA GTAAGTGACA GAGTCACAAA 1500
 AGATGCACA GAGTCCTTGG TGAACAGGCG ACCATGCTTT TCAGCTTGG AAGTCGATGA 1560
 AACATACGTT CCCAAGAGT TTAATGCTGA AACATTACCC TTCCATGCAG ATATATGCAC 1620
 20 ACTTTCTGAG AAGGAGAGAC AAATCAAGAA ACAAACCTGCA CTGTTGAGC TTGTGAAACA 1680
 CAAGCCCAAG GCAACAAAAG AGCAACTGAA AGCTGTTATG GATGATTTCG CAGCTTTTGT 1740
 AGAGAAGTGC TGCAAGGCTG ACGATAAGGA GACCTGCTTT GCCGAGGAGG GTAAAAAAGT 1800
 TGTGCTGCA AGTCAAGCTG CCTTAGGCTT ATAACATCTA CATTTAAAAG CATCTCAGCC 1860
 TACCATGAGA ATAAGAGAAA GAAAATGAAG ATCAAAAGCT TATTCATCTG TTTTCTTTTT 1920
 25 CGTTGGTGTA AAGCCAACAC 1940

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 1140 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- 35 (B) CLONE: codon-optimized 3D signal peptide-BPN' DNA sequene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

40 ATGAAGAACA CCTCTCCCT CTGCCTCCTG CTGCTCGTGG TCCTCTGCTC CCTGACCTGC 60
 AACAGCGGCC AGGCCGCTGG CAAGAGCAAC GGGGAGAAGA AGTACATCGT CGGCTTCAAG 120
 CAGACCATGA GCACCATGAG CGCCGCCAAG AAGAAGGACG TCATCAGCGA GAAGGGCGGC 180
 AAGGTACAGA AGCAGTTCAA GTACGTGGAC GCCGCCAGCG CCACCCTCAA CGAGAAGGCC 240
 GTCAAGGAGC TGAAGAAGGA CCCGAGCGTC GCCTACGTGG AGGAGGACCA CGTCGCCCAC 300
 45 GCATATGCAC AGAGCGTCCC GTACGGCGTC AGCCAGATCA AGGCCCGGC CCTCCACAGC 360
 CAGGGCTACA CCGGCAGCAA CGTCAAGTGC GCCGTCATCG ACAGCGGCAT CGACAGCAGC 420
 CACCCGGACC TCAAGGTGCG CGGCGGAGCT AGCATGGTCC CGAGCGAGAC CAACCCGTTC 480
 CAGGACACCA ACAGCCATGG CACCCACGTC GCCGCGACCG TCGCCGCCCT CACCAACAGC 540
 ATCGGCGTCC TCGGCGTCGC CCCGAGCGCC AGCCTCTACG CCGTCAAGGT ACTCGGCGCC 600
 50 GACGGCAGCG GCCAGTACAG CTGGATCATC AACGGCATCG AGTGGGCCAT CGCCAACAAC 660
 ATGGACGTCA TCACCATGAG CCTCGGCGGC CCGAGCGGCA GCGCCGCCCT CAAGGCCGCC 720
 GTCGACAAGG CCGTCGCCAG CGGCGTCGTC GTCGTCGCCG CCGCCGGCAA CGAGGGCACC 780
 AGCGGCAGCA GCAGCACCGT CGGCTACCCG GGCAAGTACC CGAGCGTCAT CGCCGTCGGC 840
 GCCGTGGACA GCAGCAACCA GCGCGCAGC TTCAGCAGCG TCGGCCCGGA GCTGGACGTC 900
 55 ATGGCCCCGG GCGTCAGCAT CCAGAGCACC CTCGCCGGCA ACAAGTACGG CGCTACAGC 960
 GGCACCAGCA TGGCCAGCCC GCACGTCGCC GCGCCCGCTG CACTCATCCT CAGCAAGCAC 1020
 CCGACCTGGA CCAACACCCA GGTCCGCAGC AGCCTGGAGA ACACCACCAC CAAGCTCGGC 1080
 GACAGCTTCT ACTACGGCAA GGGCCTCATC AACGTCCAGG CCGCCGCCCA GTGACTCGAG 1140

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- 60 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 65 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (vii) IMMEDIATE SOURCE:
 (B) CLONE: N-terminus of mature AAT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

5 Glu Asp Pro Gln Gly Asp Ala Ala Gln Lys Thr Asp Thr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:23:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

20 GCTTGACCTG TAACTCGGGC CAGGCGAGCT 30

(2) INFORMATION FOR SEQ ID NO:24:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CGCCTAGCCC GAGTTACAGG TCAAGCAGCT 30

(2) INFORMATION FOR SEQ ID NO:25:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 37 base pairs
 (B) TYPE: nucleic acid
 40 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

45 AGCTCCATGG CCGTGGCTCG AGTCTAGACG CGTCCCC 37

(2) INFORMATION FOR SEQ ID NO:26:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 55 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

60 GGGGACGCGT CTAGACTCGA GCCACGGCCA TGG 33

(2) INFORMATION FOR SEQ ID NO:27:

- 65 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

5 GCATGCAGGT GCTGAACACC ATGGTGAACA AACAC

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TTCTTGTCCC TTTCGGTCCT CATCGTCCTC CT

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

30 TGGCCTCTCC TCCAACTTGA CAGCCGGGAG CT

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

45 TTCACCATGG TGTTTCAGCAC CTGCATGCTG CA

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

55 CGATGAGGAC CGAAAGGGAC AAGAAGTGTT TG

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- 60 (A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
65 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

34-vii

CCCGGCTGTC AAGTTGGAGG AGAGGCCAAG GAGGA

35

(2) INFORMATION FOR SEQ ID NO:33:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

15 GAGGATCCCC AGGGAGATGC TGCCCAGAA

29

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CGCGCTCGAG TTATTTTGG GTGGGATTCA CCAC

34

IT IS CLAIMED:

1. A method of producing, in monocot plant cells, a mature heterologous protein s.
from the group consisting of
- 5 (i) mature, glycosylated α_1 -antitrypsin (AAT) having the same N-terminal amino acid sequence as mature AAT produced in humans and a glycosylation pattern which increases serum half-life substantially over that of mature non-glycosylated AAT;
- (ii) mature, glycosylated antithrombin III (ATIII) having the same N-terminal amino acid sequence as mature ATIII produced in humans;
- 10 (iii) mature human serum albumin (HSA) having the same N-terminal amino acid sequence as mature HSA produced in humans and having the folding pattern of native mature HSA as evidenced by its bilirubin-binding characteristics; and
- (iv) mature, active subtilisin BPN' (BPN') having the same N-terminal amino acid sequence as BPN' produced in *Bacillus*;
- 15 the method comprising:
- (a) obtaining monocot cells transformed with a chimeric gene having (i) a monocot transcriptional regulatory region, inducible by addition or removal of a small molecule, or during seed maturation, (ii) a first DNA sequence encoding the heterologous protein, and (iii) a second DNA sequence encoding a signal peptide, said first and second DNA sequences in translation-frame
- 20 and encoding a fusion protein, and wherein (i) the transcriptional regulatory region is operably linked to the second DNA sequence, and (ii) said signal peptide is effective to facilitate secretion of the mature heterologous protein from the transformed cells;
- (b) cultivating the transformed cells under conditions effective to induce said transcriptional regulatory region, thereby promoting expression of the fusion protein and secretion of the mature
- 25 heterologous protein from the transformed cells; and
- (c) isolating said mature heterologous protein produced by the transformed cells.
2. The method of claim 1, wherein said first DNA sequence encodes proBPN', said cultivating includes cultivating said transformed cells at a pH between 5-6 to promote expression and secretion of proBPN' from the cells, and said isolating step includes incubating the proBPN' under conditions effective to allow the autoconversion of proBPN' to active mature BPN'.
3. The method of claim 1, wherein said first DNA sequence encodes mature BPN', and said method further includes:
- 35 transforming said cells with a second chimeric gene containing (i) a transcriptional

regulatory region inducible by addition or removal of a small molecule, or during seed maturation, (ii) a third DNA sequence encoding the pro-peptide moiety of BPN', and (iii) a fourth DNA sequence encoding a signal polypeptide, where said fourth DNA sequence is operably linked to said transcriptional regulatory region and said third DNA sequence, and where said signal polypeptide is in translation-frame with said pro-peptide moiety and is effective to facilitate secretion of expressed pro-peptide moiety from the transformed cells;

said cultivating step includes cultivating the transformed cells at a pH between 5-6 to promote expression and secretion of BPN' and the pro-peptide moiety from the cells;

and said isolating step includes incubating the BPN' and the pro-moiety under conditions effective to allow the conversion of BPN' to active mature BPN', and isolating the active mature BPN'.

4. The method of claim 1, wherein said signal peptide is the RAmy3D signal peptide having the amino acid sequence identified by SEQ ID NO:1.

5. The method of claim 1, wherein said second DNA sequence encodes the RAmy3D signal peptide (SEQ ID NO:1) and has the codon-optimized nucleotide sequence identified by SEQ ID NO:3.

6. The method of claim 1, wherein said signal peptide is the RAmy1A signal peptide having the amino acid sequence identified by SEQ ID NO:4.

7. The method of claim 1, wherein the second DNA sequence, the first DNA sequence, or both the second and the first DNA sequence, is codon-optimized for enhanced expression in said plant.

8. The method of claim 1, wherein said transcriptional regulatory region is a promoter derived from a rice or barley α -amylase gene selected from the group consisting of the RAmy1A, RAmy1B, RAmy2A, RAmy3A, RAmy3B, RAmy3C, RAmy3D, and RAmy3E, pM/C, gKAmy141, gKAmy155, Amy32b, and HV18 genes.

9. The method of claim 8, wherein the chimeric gene further comprises, between said transcriptional regulatory region and said second DNA coding sequence, the 5' untranslated region of an inducible monocot gene selected from the group consisting of RAmy1A, RAmy3B, RAmy3C, RAmy3D, HV18, and RAmy3E.

10. The method of claim 8, wherein said chimeric gene further comprises, downstream of the sequence encoding said fusion protein, the 3' untranslated region of an inducible monocot gene derived from a rice or barley α -amylase gene selected from the group consisting of the RAmy1A, RAmy1B, RAmy2A, RAmy3A, RAmy3B, RAmy3C, RAmy3D, and RAmy3E, pM/C, gKAmY141, gKAmY155, Amy32b, and HV18 genes.

11. The method of claim 1, wherein said cultivating includes culturing the transformed plant cells in a sugar-free or sugar-depleted medium, the transcriptional regulatory region is derived from the RAmy3E or RAmy3D gene, the 5' untranslated region is derived from the RAmy1A gene and has the sequence identified by SEQ ID NO:5, and the 3' untranslated region is derived from the RAmy1A gene.

12. The method of claim 1, wherein the transformed cells are aleurone cells of mature seeds, the transcriptional regulatory region is upregulated by addition of a small molecule to promote seed germination, and said cultivating includes germinating said seeds, either in embryonated or de-embryonated form.

13. The method of claim 12, wherein the transcriptional regulatory region is a rice α -amylase RAmy1A promoter or a barley HV18 promoter, and said small molecule is gibberellic acid.

14. A mature heterologous protein produced by the method of claim 1, wherein said protein is selected from the group consisting of:

(i) mature glycosylated α_1 -antitrypsin (AAT) having the same N-terminal amino acid sequence as mature AAT produced in humans and having a glycosylation pattern which increases serum half-life substantially over that of non-glycosylated mature AAT;

(ii) mature glycosylated antithrombin III (ATIII) having the same N-terminal amino acid sequence as mature ATIII produced in humans; and

(iii) mature glycosylated subtilisin BPN' (BPN') having the same N-terminal amino acid sequence as BPN' produced in *Bacillus*;

wherein said protein has a glycosylation pattern characteristic of proteins produced in said monocot plant.

15. The method of claim 1, wherein said monocot plant cells are transformed rice, barley, corn, wheat, oat, rye, sorghum, or millet cells.

16. The method of claim 1, wherein said monocot plant cells are transformed rice or barley cells.

5 17. Plant cells capable of producing the mature heterologous protein according to the method of claim 1, wherein said cultivating includes culturing the transformed plant cells in a sugar-free or sugar-depleted medium, the transcriptional regulatory region is derived from the RAmy3E or RAmy3D gene, the 5' untranslated region is derived from the RAmy1A gene and has the sequence identified by SEQ ID NO:5, and the 3' untranslated region is derived from the RAmy1A gene.

10

18. Seeds capable of producing the mature heterologous protein according to the method of claim 1, wherein said transformed cells are aleurone cells, the transcriptional regulatory region is upregulated by addition of a small molecule to promote seed germination, and said cultivating includes germinating said seeds, either in embryonated or de-embryonated form.

15

3D Signal Peptide

| |
|---|
| ATG AAG AAC ACC AGC AGC TTG TGT TTG CTG CTC CTC CTG AGC TGC AGC TGT AAC TCG GGC CAG GCG |
| ATG AAG AAC ACC TCC CTC TGC CTC CTC CTG CTC TGC TCC CTC TGC AAC AGC GGC CAG GCC |
| Met Lys Asn Thr Ser Ser Leu Cys Leu Leu Leu Val Leu Cys Ser Leu Thr Cys Asn Ser Gly Gln Ala |

Fig. 1





Fig. 2

2/11

**Fig. 3A**

3/11

p3D - AAT
7195 bp




Fig. 3B

4/11




Fig. 4




Fig. 5

SUBSTITUTE SHEET (RULE 26)

6/11




Fig. 6




Fig. 7

N ----> E-D-P-Q-G-D-A-A-Q-K-T-D-T

Fig. 8

8/11

TP309 - sucrose
TP309 + sucrose
9A - sucrose
9A + sucrose
32B - sucrose
32B + sucrose
46 - sucrose
46 + sucrose
42 + sucrose
42 + sucrose
Mol. Weight
AT III (1ng)




Fig. 9

9/11






Fig. 10

10/11

**Fig. 11A****Fig. 11B**

11/11

| Mol. Weight | 3-11-2 | | | | |
|---------------------|--------|-------|-------|--------|-------|
| HSA Standard (5 ng) | 24 hr | 48 hr | 72 hr | 120 hr | TP309 |




Fig. 12

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/03068

| | | |
|--|--|--|
| A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/82 C12N15/57 C12N15/15 C12N15/14 C12P21/02 | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | |
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C12P | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used) | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | WO 95 14099 A (RODRIGUEZ RAYMOND L ;UNIV CALIFORNIA (US)) 26 May 1995 | 1,4,6,8-18 |
| Y | see the whole document | 1,5 |
| Y | WO 92 01042 A (NOVONORDISK AS) 23 January 1992 see page 6, line 15 - line 19 | 1 |
| Y | JENSEN L G ET AL: "TRANSGENIC BARLEY EXPRESSING A PROTEIN-ENGINEERED, THERMOSTABLE (1,3-1,4)-BETA-FLUCANASE DURING GERMINATION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 8, April 1996, pages 3487-3491, XP002024710 see the whole document | 5 |
| -/-- | | |
| <div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div> | | |
| * Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div> | | |
| Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">30 June 1998</div> | | Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">14/07/1998</div> |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | | Authorized officer <div style="text-align: center; font-weight: bold;">Maddox, A</div> |

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03068

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| P,X | <p>TERASHIMA M ET AL: "Production of functional human alpha-1-antitrypsin by rice cell culture; expression and protein secretion in callus culture (conference abstract)"</p> <p>ABSTR.PAP.AM.CHEM.SOC.;(1997) 214 MEET., PT.1, AGFD018 CODEN: ACSRAL ISSN: 0065-7727 AMERICAN CHEMICAL SOCIETY, 214TH ACS NATIONAL MEETING, LAS VEGAS, NV, 7-11 SEPTEMBER, 1997., XP002069835 see abstract 018</p> <p style="text-align: center;">---</p> | 1,4, 8-10, 14-17 |
| A | <p>THOMAS, B. R. ET AL: "Gene regulation and protein secretion from plant cell cultures: the rice alpha - amylase system" ADVANCES IN PLANT BIOTECHNOLOGY, (1994) PP. 37-55. STUDIES IN PLANT SCIENCE 4. 85 REF. PUBLISHER: ELSEVIER SCIENCE. AMSTERDAM ISBN: 0-444-89939-1, XP002069833 see the whole document</p> <p style="text-align: center;">---</p> | 1,11 |
| A | <p>CHAN M-T ET AL: "Novel gene expression system for plant cells based on induction of alpha-amylase promoter by carbohydrate starvation." JOURNAL OF BIOLOGICAL CHEMISTRY 269 (26). 1994. 17635-17641. ISSN: 0021-9258, XP002069821 see the whole document</p> <p style="text-align: center;">---</p> | 1,11 |
| A | <p>US 5 460 952 A (YU SU-MAY ET AL) 24 October 1995 see the whole document</p> <p style="text-align: center;">---</p> | 1,11 |
| A | <p>WO 90 01551 A (ROGERS JOHN C) 22 February 1990 see the whole document</p> <p style="text-align: center;">---</p> | 1,12 |
| A | <p>WO 91 02066 A (MOGEN INT) 21 February 1991 see the whole document</p> <p style="text-align: center;">---</p> | 1 |
| A | <p>EP 0 348 348 A (CIBA GEIGY AG) 27 December 1989 see examples 41-45</p> <p style="text-align: center;">-----</p> | 1 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. .ational Application No

PCT/US 98/03068

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|--|--|
| WO 9514099 A | 26-05-1995 | US 5693506 A AU 1289295 A CA 2176834 A EP 0788550 A JP 9509565 T | 02-12-1997 06-06-1995 26-05-1995 13-08-1997 30-09-1997 |
| WO 9201042 A | 23-01-1992 | AU 8219291 A | 04-02-1992 |
| US 5460952 A | 24-10-1995 | JP 7143895 A US 5712112 A | 06-06-1995 27-01-1998 |
| WO 9001551 A | 22-02-1990 | AU 638409 B AU 4037289 A EP 0428572 A JP 4500153 T US 5677474 A | 01-07-1993 05-03-1990 29-05-1991 16-01-1992 14-10-1997 |
| WO 9102066 A | 21-02-1991 | NL 8901932 A EP 0436003 A JP 4502861 T US 5650307 A US 5716802 A US 5763748 A | 18-02-1991 10-07-1991 28-05-1992 22-07-1997 10-02-1998 09-06-1998 |
| EP 0348348 A | 27-12-1989 | AU 631551 B AU 3656889 A DK 302289 A IL 90640 A JP 2046238 A | 03-12-1992 21-12-1989 28-02-1990 04-01-1998 15-02-1990 |

THIS PAGE BLANK (USPTO)